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Abstract
Ski and SnoN are two highly related transcription factors that are transcribed
from two separate genes named SKI and SKIL, respectively. They are both co-repressors
of the Smad-mediated transforming growth factor beta (TGFβ) signaling pathway.
Originally they were classified as oncogenes as they have the ability to transform quail
fibroblasts. However, they have also been found to have anti-proliferative properties so
they are also considered tumor suppressors. They are involved in normal growth and
development and thought to be essential as there is evidence that a homozygous mouse
knockout of either SKI or SKIL is embryonic lethal. Both Ski and SnoN have been found to
be overexpressed in some cancers. This overexpression has been found to be prognostic
in some cases. Another prognostic factor in certain cancers is the cytoplasmic
localization of these normally nuclear proteins. Other than with the TGFβ signaling
pathway, Ski and SnoN are known to have interactions with retinoic acid receptor
signaling and the retinoblastoma protein. In order to obtain a better understanding of
Ski and SnoN we have studied several aspects of the proteins. First, we identified the
nuclear localization signal (NLS) of Ski and proved that this sequence was both necessary
and sufficient for nuclear localization. Next, we looked into the correlation of Ski
subcellular location and serine phosphorylation status. Here we found that serine
phosphorylated Ski is found predominately in the cytoplasm. Finally, we looked at
possible involvement of Ski and SnoN in the pediatric cancer rhabdomyosarcoma (RMS).
We found there was expression of both of these proteins in cell lines derived from the
cancer and in tumor tissue samples. We also found that Ski protein levels in RMS tumor
vii

tissue are negatively correlated with RMS tumor group. The data from the Ski
phosphorylation studies suggest that this modification may work with the NLS to
regulate the subcellular location of Ski. Misregulation of this process may be responsible
for the cytoplasmic localization of Ski that we found in RMS.
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Chapter 1: Ski and SnoN
1.1 Proteins and Post-translational Modifications
The Ski protein family is named for the founding member, v-Ski, and in humans
the family consists of Ski, SnoN, SnoA, and SnoI (Nomura et al., 1989; Pearson-White,
1993). These proteins were found when looking for the human homolog to v-ski
(Nomura et al., 1989). v-ski and human Ski show 91% protein homology. Ski was named
after the Sloan Kettering Institute where it was discovered. Sno is short for Ski-related
novel, and is also called Ski-like protein or Skil. SnoN (Ski-related novel non-Alu
containing) does not have an ALU containing motif while SnoA (Ski-related novel Alu
containing) has the Alu motif. SnoI contains an insertion (Ski-related novel with
insertion) with an in-frame termination codon resulting in a truncated protein. These
proteins are transcription factors that act as co-repressors of the Smad mediated TGFβ
signaling pathway (Akiyoshi et al., 1999; Luo et al., 1999; Stroschein et al., 1999). The Ski
protein is the largest of the family and consists of 728 amino acids. SnoN contains 684
amino acids while SnoA and SnoI have 415 and 399 amino acids respectively. There are
splicing variants of the Ski and SnoN proteins in other species that are not found in
humans. Both Ski and SnoN contain nuclear localization signals (NLS) and are found in
the nucleus of normal cells (Barkas et al., 1986; Krakowski et al., 2005; Nagata et al.,
2006). Despite the conservation between the two proteins, the NLS is not conserved. A
pair-wise protein BLAST between the human Ski and SnoN revealed that 37% of the
amino acids are identical while 55% of the amino acids were identical or had
1

conservative changes (Tatusova and Madden, 1999). And a BLAST between the chicken
homologs reported 42% identical amino acids and 60% that were identical or had
conservative changes.
There are several functional domains in Ski and SnoN including the familial Ski
domain also called the Dachshund homology domain (DHD or DACH) (see Figure 1)
(Medrano, 2007). The Ski domain, which is essential for transformation, is roughly 100
amino acids long, contains a conserved CLPQ motif, and is found toward the N-terminus
of the protein. There is a SAND-like (Sp100, Aire-1, NucP41/75, DEAF-1) domain in the
region containing amino acids 219-312 that was discovered by 3-dimensional homology
when examining the crystallized structure of this peptide (Wu et al., 2002). Also found in
the Ski protein are a proline rich domain, three leucine zipper-like domains, two tandem
helix-loop-helix motifs, a basic amino acid region, a serine/threonine domain, three
tandem 25 amino acid repeats, and two alpha helical domains. The Ski domain is
responsible for protein interaction with Smad4, PML, MeCP2, SKIP, pRb, HIPK-2, N-CoR,
FHL2, and mSin3. Ski has multiple post-translational modifications including
phosphorylation and sumoylation (Sutrave et al., 1990a).

2

SAND Domain

Figure 1: Ski domains and interactions [adapted from (Medrano, 2007)].
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The overlapping 25 amino acid repeats and two alpha helical domains are
located in the C-terminal domain of the protein and are thought to be responsible for
the dimerization of Ski (Heyman and Stavnezer, 1994). In order to investigate this
interaction a series of eight GST tagged deletion constructs were generated and
expressed

in

cell

lines.

When

chemically

cross-linked

proteins

were

immunoprecipitated, only the constructs that contained both the repeats and the alpha
helical domains exhibited strong dimerization capability. Further biochemical studies
including hydrodynamic, cross-linking, and circular dichroism support this model (Zheng
et al., 1997a). Ski can also form heterodimers with SnoN, and SnoN can form
homodimers, although this requires an upstream element in addition to the C-terminal
domain (Cohen et al., 1999). This work, however, suggests that the Ski:SnoN
heterodimer is more stable than either of the homodimers. They also demonstrate that
the heterodimer will not only bind a GTCT element, but will also have a stronger
transforming ability in chicken embryo fibroblasts than either of the Ski or SnoN
homodimers. It should be noted that functions of Ski and SnoN other than DNA binding
and transformation were not examined in these studies.
The SKI and SKIL genes are thought to be paralogs and therefore they share
many of the same protein domains. There is only one SKI/SKIL gene in Drosophila and it
has more homology with the human SKIL than the human SKI gene, suggesting that SKIL
is the founding member of the family (Takaesu et al., 2006). The protein interacting
domains of SnoN have not been mapped as extensively as these, but as can be seen
4

from the protein sequence comparison, much of the general homology is conserved
(see Figure 2). This is also apparent in the similarities in function between the two
proteins. However, one notable difference is a region at the N-terminus of SnoN that
contains an NLS is missing in Ski (Krakowski et al., 2005). There are also gaps in SnoN
compared to Ski in the alignment that probably affect interaction with other proteins
leading to the slight difference in function seen between the proteins.

Ski
SnoN

Figure 2: Graphical representation of Ski/SnoN protein alignment from NCBI BLAST 2 sequences. The blue
sections are regions that are similar while the red regions are gaps in the similarities.
(http://blast.ncbi.nlm.nih.gov/Blast.cgi)

The function of Ski and SnoN can be modified by post-translation modifications
including phosphorylation and sumoylation. Phosphorylation is a very common
modification, yet is very diverse in the types of functions that it can regulate including
enzyme activity, protein-protein interactions, and protein degradation (Lodish, 2008).
Ski phosphorylation was first examined in the chicken homolog of Ski. Chicken embryo
fibroblasts were transfected with plasmids containing chicken ski cDNA (Sutrave et al.,
1990a). The cells were labeled with

32

Pi in order to identify phosphorylated proteins.

Extracts from the transfected cells were immunoprecipitated (IP) with antisera
generated against Ski peptides and the IP eluates were electrophoresed the on an SDSpolyacrylamide gel. Proteins were extracted from the gel, hydrolyzed with hydrochloric
acid, and analyzed on cellulose plates. The results indicated that chicken Ski is
phosphorylated only on serine residues and not on threonine or tyrosine. The other
5

study of Ski phosphorylation was in the context of the cell cycle (Marcelain and Hayman,
2005). In this study the authors overexpressed a T7-tagged human Ski in the MG63
osteosarcoma cell line and then synchronized the cells with nocodazole. They collected
protein extracts at different phases of the cell cycle and performed a Western blot
showing that there are two different molecular weights of Ski. The larger band
disappeared when the extracts were treated with a phosphatase, suggesting that this
form is phosphorylated. When phosphatase inhibitors were added to the extracts and
phosphatase, the larger band did not disappear. The prevalence of the larger band
throughout the cell cycle differed in the two cell lines they examined. Further
examination suggested that Ski was phosphorylated by either the Cdk1-cyclin B kinase
complex, or by another kinase which itself is regulated by Cdk1. Neither of these studies
examined the effect of phosphorylation on subcellular localization.
SnoN has also been shown to be modified by the small ubiquitin-like modifier
(SUMO) (Hsu et al., 2006). This post-translational modification has been associated with
the regulation of many cell processes including nuclear-cytosolic transport,
transcriptional regulation, apoptosis, protein stability, response to stress, and
progression through the cell cycle (Hay, 2005). Studies have shown that SnoN is
sumoylated at two separate lysines and that the modification helps to regulate SnoN’s
function in transcription repression (Hsu et al., 2006; Wrighton et al., 2007). This has
been shown to be promoter-specific and to strongly inhibit myogenin transcription (Hsu
et al., 2006). Sumoylation of Ski has not been reported in the literature, but there is
6

evidence that it may occur. There are three putative sumoylation sites located within
the tandem repeats near the carboxy terminus of Ski (Medrano, 2007). Sumoylation is
reportedly required at one of these sites for protein stability (Medrano, 2007).
Smad-mediated TGFβ signaling has been shown to induce Ski and SnoN protein
degradation (Sun et al., 1999). Ski is stabilized during mitosis by Cdc34 but degraded
during interphase, leading to a cell-cycle dependent regulatory process (Macdonald et
al., 2004; Marcelain and Hayman, 2005). Degradation of SnoN by the proteosome is
preceded by ubiquitination of SnoN by one of two different E3 ubiquitin ligases. Smurf2
was the first E3 shown to mediate the ubiquitination of SnoN through an interaction
with Smad2 (Bonni et al., 2001). It was also shown that the anaphase promoting
complex (APC) can ubiquitinate SnoN when recruited by Smad3 (Stroschein et al., 2001;
Wan et al., 2001).

1.2 Genes/Gene Expression/Transcripts
The SKI gene was initially mapped to 1q22-q24 using Southern blot analysis to
probe human spermatocyte pachytene and lymphocyte metaphase chromosomes with
a v-SKI probe (Chaganti et al., 1986). It was later remapped to 1p36.3 using the radiation
hybrid (RH) method (Shinagawa et al., 2001). Only one functional protein has been
reported from the SKI gene in humans while the chicken version has been shown to
have several splicing variants (Sutrave and Hughes, 1989). According to the Celera build,
the SKI gene extends from 351748 to 432073 on the positive strand, effectively spanning
80,325 bases (NCBI Accession AC_000044.1). Intron 1 is unusually large consisting of
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73,242 bases. The mature mRNA is 2187 bases long and contains eight exons. The
3’untranslated region (UTR) has several A-rich regions that can cause false-priming
when using oligo(dT) to prime the reverse-transcriptase (RT) reaction. It has also been
reported that the GC-rich region in the 5’UTR may cause processivity problems with the
RT enzyme (Nomura et al., 1989). The mature mRNA may be much larger than has been
reported. One report states that the 3’UTR is much longer, with a total mRNA length of
more than 4000 bases (Grimes et al., 1992). The gene is highly conserved through
different species, as can be seen in Table 1. Although over 3000 single nucleotide
polymorphisms (SNPs) for SKI have been submitted to NCBI, there has been only one
report examining SNPs in SKI which was in the context of the risk of orofacial clefting (Lu
et al., 2005). They found one SNP in the first exon that was associated with a decreased
risk of orofacial clefting.
Table 1: SKI conservation from HomoloGene at NCBI (http://www.genecards.org/cgi-bin/carddisp.pl?gene=SKI)

Gene
Species
Homo sapiens
vs. Canis lupus familiaris
vs. Bos taurus
vs. Mus musculus
vs. Gallus gallus
vs. Danio rerio

Identity (%)
Symbol Protein DNA
SKI
SKI
93.4 89.8
SKI
90.2 89.3
Ski
93.4 88.8
SKI
83.6
76
skia
73
72

According to Build 36.3 of the Human Genome Project, the SKIL gene is located
from

9,907.9

to

9,909.43

on

chromosome

3q26

(http://www.ncbi.nlm.nih.gov/genome/guide/). There is disagreement as to the size
and exon content of the mRNAs from the SKIL gene. Like the SKI gene, the SKIL gene has
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a GC-rich region in the 5’UTR that appears to complicate RT reactions. According to
NCBI, the mature mRNA coding for SnoN is 3111 bases long, has seven exons, and the
coding sequence extends from 672 to 2726. This version of the mRNA also has an intron
within the 5’UTR. The mRNA coding for SnoI is alternatively spliced and contains a
premature stop codon (Pearson-White, 1993). The mRNA for SnoA is also alternatively
spliced. The SKIL gene is highly conserved throughout different species as can be seen in
Table 2 (NCBI, 2008).
Table 2: SKIL conservation from HomoloGene at NCBI (http://www.genecards.org/cgi-bin/carddisp.pl?gene=SKIL)

Gene
Species
Homo sapiens
vs. Pan troglodytes
vs. Canis lupus familiaris
vs. Bos taurus
vs. Mus musculus
vs. Rattus norvegicus
vs. Gallus gallus
vs. Danio rerio

Symbol
SKIL
SKIL
SKIL
SKIL
Skil
Skil
SKIL
LOC556403

Identity (%)
Protein DNA
99.4
91.5
90.9
89
89.7
76.2
48.3

99.4
90.5
91.2
85.4
85.5
75.3
52.2

SKIL has been found to be an immediate early serum response gene in quiescent
fibroblasts (Pearson-White and Crittenden, 1997). SKI does not exhibit this response. Ski
expression has been shown to be induced by phorbol 12-myristate 13-acetate (PMA) in
myeloid cell lines (Namciu et al., 1994). Ski expression is also up-regulated in muscle
differentiation (Ambrose et al., 1995; Namciu et al., 1995). SnoN expression is upregulated upon serum deprivation in myoblasts, and upon serum stimulation in
fibroblasts (Mimura et al., 1996; Pearson-White and Crittenden, 1997). Ski and SnoN are
both up-regulated during liver regeneration, while they are down-regulated in the
9

fibrotic kidney (Macias-Silva et al., 2002; Yang et al., 2003). The up-regulation of Ski was
correlated with the progression of esophageal squamous cell carcinoma while the upregulation of SnoN was correlated with a negative prognosis in the same cancer (Akagi
et al., 2008; Fukuchi et al., 2004). SKI gene amplification is a negative prognostic marker
in early colorectal cancer (Buess et al., 2004). Both Ski and SnoN have been found to be
up-regulated in melanoma (Boone et al., 2008; Chen et al., 2003; Fumagalli et al., 1993;
Heider et al., 2007; Poser et al., 2005; Reed et al., 2001; Reed et al., 2005).
Ski and SnoN were found to be involved in various aspects of development and
their gene expression patterns throughout development have been examined in lower
animals. Data from studies of Xenopus laevis indicate that Ski is maternally regulated
during early development and then widely expressed in adult tissues (Sleeman and
Laskey, 1993). In mouse embryos Ski is expressed in all tissues with varying expression
levels at different developmental stages (Lyons et al., 1994). Gene expression has also
been performed in tissues using microarrays as can be seen in Figures 3 and 4 (Shmueli
et al., 2003). These charts were created using the GCRMA method of gene expression
quantification and normalization. The median expression of the samples examined is
arbitrarily set at 7 and the rest of the transcripts are graphed relative to this value. This
illustrates the relative expression of mRNA transcripts for both Ski and SnoN in normal
and tumor tissue and that there is mRNA for both Ski and SnoN in all tissues examined.
An interesting observation of these charts is that the relative mRNA levels of Ski and
SnoN are very similar in the different tissues with the notable exception of skeletal
10

muscle where Ski has a higher than average mRNA level and SnoN has a lower than
average mRNA level.
There are three other genes that have been found that are related to SKI and
contain the Ski domain. They are Dach1, Fussel-15, and Fussel-18 (Zhang and Stavnezer,
2008). The Dach1 gene has been mapped to 13q22 and the mRNA is expressed
predominately in adult kidney, heart and placenta with weaker expression in brain, lung,
skeletal muscle, and pancreas (Kozmik et al., 1999). Expression studies in mice suggest
that it may be involved in eye and limb development (Hammond et al., 1998). The
protein consists of 706-amino acids and has a predicted molecular weight of 73 kDa
(Kozmik et al., 1999). The Fussel-18 gene was mapped to 18q22.1 and encodes a 297amino acid protein (Arndt et al., 2005). The mRNA is expressed only in neural tissue and
the protein has been found to also inhibit TGFβ signaling. The Fussel-15 gene was
mapped to 15q23 and shares a high homology with the Fussel-18 gene, although it
encodes a much larger, 921-amino acid, protein (Arndt et al., 2007). mRNA expression of
Fussel-15 is detected in adult Purkinje cells of the cerebellum where the protein has
been found to interact with Smad1, Smad2, and Smad3 protein, inhibiting bone
morphogenic protein (BMP) signaling.
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Figure 3: Ski gene expression as determined by Affymetrix gene chip 204270_at
(http://biogps.gnf.org/#goto=genereport&id=6497). The horizontal axis indicates fluorescence intensity.

12

Figure 4: Sno gene expression as determined by Affymetrix gene chip 215889_at
(http://biogps.gnf.org/#goto=genereport&id=6498). The horizontal axis indicates fluorescence intensity.
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1.3 Function
1.3.1 Overview

Figure 5: Protein interactions known and predicted between Ski and other proteins from the STRING 8.0 website
(Jensen et al., 2008). Thicker connecting lines indicate a stronger probability of interaction.
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Figure 6: Protein interactions known and predicted between SnoN and other proteins from the STRING 8.0 website
(Jensen et al., 2008). Thicker connecting lines indicate a stronger probability of interaction.
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Some of the functions of Ski and SnoN can be inferred from the protein
interaction diagrams (see Figures 5 and 6). The width of the lines between the proteins
signifies the confidence of the interaction, with the wider lines indicating stronger
evidence of interaction. The main interaction partners are the Smad proteins that
mediate signaling from transforming growth factor beta (TGFβ) receptors. This family of
transmembrane receptors consists of TGFβ 1 and 2, activin 1 and 2, and bone
morphogenic protein (BMP) 1 and 2 (Massague, 2008). The ligands for these receptors
consist of more than 30 members and include activin, nodal, lefty, myostatin, TGFβ,
BMP, anti-muellerian hormone (AMH, also known as MIS), and other growth and
differentiation factors (GDF). The receptors are classified as either type I or type II, with
the latter having a binding site for the corresponding ligand. Binding of the type II
receptor with a compatible ligand results in receptor dimerization and subsequent
phosphorylation of a type I receptor. Upon phosphorylation, the receptor dimer is now
considered activated, and the activated receptor then phosphorylates receptor Smads
(R-Smads), which then bind to a co-Smad and translocate into the nucleus. There are
also inhibitor Smads (I-Smads) that compete with Co-Smad binding and recruit Smad
ubiquitination regulatory factors (Smurfs) to the TGFβ receptors and mark them for
degradation. In the nucleus, the Smad complex binds with co-factors that regulate DNA
binding specificity and function. The end result of the signaling pathway is context and
cell type specific. It is also dependent on the co-factors expressed in the cell, resulting in
cell growth, cell differentiation, apoptosis, and/or general homeostasis regulation (Luo,
2004).
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Ski’s ability to regulate Smad-mediated TGFβ signaling involves the recruitment
of histone deacetylase (HDAC) to Ski/Smad complexes on DNA (Akiyoshi et al., 1999). Ski
also inhibits the interaction between Smad3 and transcriptional activator p300, blocking
transcription initiation. The Ski/HDAC complex has been shown to also contain NCoR/SMRT and mSin3A (Nomura et al., 1999). The v-Ski viral protein lacks the domain
that interacts with mSkin3A and therefore acts in a dominant negative manner in
regulating Ski activity. There is also evidence that retinoblastoma protein (pRb) is in an
inhibitory complex with Ski, Sin3A, and HDAC that blocks pRb mediated transcription
(Tokitou et al., 1999).
The Ski interacting protein (Skip), which is also known as SNW domain containing
1 (SNW1), is a transcription factor that appears to have opposing function to Ski and
SnoN in the Smad mediated TGFβ signaling pathway (Leong et al., 2001). Skip’s function
appears to be related to its interaction with not only Ski and SnoN but also the Smad
proteins (Dahl et al., 1998b; Prathapam et al., 2001). Another important interaction
appears to be a complex formed between pRb, Skip, and Ski that represses pRb’s
transcriptional activity (Prathapam et al., 2002). This complex can also bypass the G1
and flat cell phenotype mediated by pRb.
1.3.2 Transformation
The Ski containing avian virus was first discovered while examining SloanKettering viruses (SKVs) (Li et al., 1986). These are a group of transforming retroviruses
that were isolated from chicken embryo cells that had been infected with the avian
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leukosis virus transformation-defective Bratislava 77 (tdB77). A conserved sequence was
found in several of the isolated viruses that had a cellular homolog in the chicken
genome. This sequence was not thought to be related to any of the known oncogenes at
the time, although later it was said to have limited sequence and structural similarities
to v-myc (Stavnezer et al., 1989). Infection of chicken embryo cells with the viruses
induced focus formation in monolayer culture and colony formation in soft agar. These
results led to the classification of Ski as an oncogene. SnoN was also found to have
transforming abilities, but only at high expression levels (Boyer et al., 1993). This ability
of the Ski gene family encoded proteins to transform cells was subsequently found to be
the result of their capacity to inhibit Smad-mediated TGFβ signaling (He et al., 2003).
This pathway has many diverse functions, including roles in regulation of epithelial and
neural tissues, wound repair, and the immune system (Massague, 2008). In the context
of cancer, the TGFβ pathway is important because it contributes to the regulation of
cellular

proliferation,

differentiation,

survival,

adhesion,

and

the

cellular

microenvironment. Ligands in the TGFβ family bind to cell surface receptors in the TGFβ
family. This interaction leads to the activation of the receptors via dimerization and
subsequent cross-phosphorylation of the receptors. The activated receptors then
phosphorylate Receptor-Smads (R-Smads) which are anchored in close proximity by a
Smad anchor for receptor activation (SARA). The activated R-Smad binds to a Co-Smad
and translocates to the nucleus. In the nucleus the Smads bind to Smad binding
elements (SBE) on DNA in a complex with other cofactors. The cofactors in the complex
determine the end result of the signal. Ski and SnoN are cofactors that interact with R18

Smads (Smad 2 and Smad 3) and the Co-Smad (Smad 4) (He et al., 2003). This interaction
has been shown to be responsible for their transforming activities.
1.3.3 Myogenesis
In addition to having transformation properties, Ski was also found to have
myogenic properties that were first demonstrated in quail embryo cells (Colmenares
and Stavnezer, 1989). Although Ski has potent myogenic activities, SnoN is only weakly
myogenic in chicken embryo fibroblasts or quail embryo cells and requires high levels of
expression to induce myogenesis (Boyer et al., 1993). Transgenic mice overexpressing
Ski with a murine sarcoma virus (MSV) long terminal repeat (LTR) promoter have also
indicated that Ski has a role in myogenesis (Sutrave et al., 1990b). This particular model
system resulted in a selective hypertrophy of type II fast skeletal muscle fibers. The
researchers also found an increase in muscle fiber diameter but not an increase in fiber
number. This would indicate that Ski has a myogenic effect on the muscle rather than a
mitogenic effect. The muscle fiber structure of transgenic mice overexpressing Ski was
examined in detail and it was discovered that there was a reduction in the fraction of
contractile material, poor intracellular alignment of Z-discs, and a concomitant
reduction in contractile force per cross-sectional area (Bruusgaard et al., 2005).
However, the promoter used to create the transgenic mice appears to have a large
impact on the resultant phenotype (Sutrave et al., 2000). Transgenic mice with either a
skeletal actin alpha (αsk-actin) promoter or an albumin promoter controlling Ski failed to
produce a muscular phenotype. A transgenic bovine was also generated using pronuclei
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microinjection (Bowen et al., 1994). The single surviving transgenic calf was normal at
birth but then developed muscular hypertrophy 8 weeks after birth and subsequently
experienced muscle degeneration. At ten weeks of age the animal had periods of
weakness to the point that it could not stand without support. At fifteen weeks the
animal was euthanized for humane considerations. Histological examination of the
animal revealed hypertrophy of most muscles. There were also a small number of
degenerating fibers and mononuclear cells at the periphery of the fibers.
One of the mechanisms behind the myogenic activities of Ski and SnoN appears
to be related to their functions as transcription factors. v-Ski was found to induce MyoD
and myogenin expression and induce myotube formation (Colmenares et al., 1991).
However, a mutated v-Ski that also induced MyoD and myogenin expression failed to
induce myotube formation, indicating that another function is required for myotube
formation. It has been found that Ski has the ability to upregulate myosin light chain 1/3
(MLC) and muscle creatine kinase (CK) gene transcription (Engert et al., 1995). Ski can
also increase the gene transcription of the transcription factor myogenin (Ichikawa et
al., 1997). The domain of Ski that is responsible for the regulation of myogenin was
determined to be in exon 1 (Zheng et al., 1997b). This domain was found to form a
globular structure and share a portion of its sequence with the domain that is
responsible for transformation. Recent studies indicate that Ski’s myogenic activities are
independent of its interaction with the TGFβ signaling pathway (Kobayashi et al., 2007).
Proteins of the myoD family and the myocyte enhancer factor E (MEF2) family are also
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believed to form a complex with Ski in order to repress myogenin mRNA transcription
(Kobayashi et al., 2007). Ski’s ability to suppress histone deacetylases (HDAC),
specifically HDAC1, is also thought to be involved in the regulation of myogenin
expression (Kobayashi et al., 2007). Another possible mechanism for the skeletal muscle
hypertrophy is a low rate of proteolysis in the affected muscles. Ski overexpressing
transgenic mice were found to have decreased expression and activity of proteolytic
systems in fast twitch muscle compared to normal controls (Costelli et al., 2003). Protein
synthesis does not appear to be affected in the transgenic mice.
Ski has also been implicated in skeletal muscle regeneration (Soeta et al., 2001).
A mouse model of muscle injury was created by injecting mice with 500 µL of hypertonic
saline solution in the femoral muscle. mRNA levels of Ski increased three-fold, two days
after injury and returned to normal by two weeks post-injury. This involvement may
contribute to some of the symptoms that are seen in overexpressing Ski transgenic
animals. As mentioned before, fiber degeneration occurs after the hypertrophic muscle
phenotype presents. MyoD null mice have defective satellite cell differentiation so they
are unable to produce new myoblasts in skeletal muscle (Megeney et al., 1996; Sabourin
et al., 1999). When MyoD-null mice are used to generate Ski transgenics, the
hypertrophic muscle phenotype is increased and there is also an increase in the
degeneration of muscle fibers (Charge et al., 2002). This would indicate that satellite
cells are able to repair the degeneration and that Ski may be involved in the process.
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Less is known about SnoN and its involvement in myogenesis. SnoN is a much
weaker myogenic factor than Ski and requires a much higher expression level to induce
myogenesis (Boyer et al., 1993). Transgenic mice expressing SnoN under control of a
simian virus 40 (SV40) enhancer/promoter displayed a variety of phenotypes (Kano et
al., 1998). One of the mice had smaller soleus muscles and a decrease in type I skeletal
muscle fiber compared to a normal mouse. This compares with the Ski transgenic mice
that showed hypertrophy of the type II fibers. Another one of the mice had retarded
growth. Recently it was discovered that SnoN is sumoylated at lysines 50 and 383 by
Ubc9, PIAS1, and PIASx (Hsu et al., 2006; Wrighton et al., 2007). This post-translational
modification has the greatest effect on SnoN’s myogenic properties, specifically a
decrease in myogenin transcription when sumoylation is blocked. There was little effect
on the ability of SnoN to repress TGFβ- induced signaling indicating that SnoN’s
myogenic properties, like Ski’s, are likely separate from its ability to repress TGFβ
signaling.
Transcription levels of Ski and SnoN have also been shown to change during
myogenesis. When C2C12 mouse myoblast cells are grown to confluence and serum
deprived, mRNA levels of SnoN transiently increased 25 fold over basal levels as
demonstrated by competitive RT-PCR (Mimura et al., 1996). The same increase in SnoN
transcripts was seen in C3H10T 1/2 fibroblast cells, although they do not differentiate
into myotubes. It is thought that the increase in SnoN may be necessary for entry into
the G0 phase of the cell cycle.
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1.3.4 Development
Not all of the functions of Ski and SnoN in development have been ascertained.
Many knockout, knockdown, and overexpression studies have greatly increased our
knowledge in this area. Much of this work has been performed in mice, although the
different splice variants in mice compared to humans suggest disparate functions.
Homozygous Ski knockout mice demonstrated an abnormal curvature of the spine, a
10% decrease in size, a flat, foreshortened snout, an abnormal jaw, and had prenatal
lethality (Berk et al., 1997). 85% of the homozygous mouse pups showed exencephaly,
abnormal posture, and an abnormal facial morphology. The other 15% also showed
facial clefting defects that ranged from complete frontonasal clefting to mild clefting of
the lip and nose. All of the homozygous knockouts died shortly after birth regardless of
the severity of the defect. There was also a lower than expected number of homozygous
pups, indicating an approximately 25% embryonic lethality from the knockout. A small
percentage of the heterozygous knockouts had exencephaly or facial clefting. A
decrease in skeletal muscle mass was seen in 50-60% of homozygous knockouts, while
there was no loss of skeletal muscle mass in heterozygous knockouts. Histologically, the
mice with reduced muscle mass had smaller diameter muscle fibers and more space
between the fibers. Many of the fibers also appeared to be shorter and disorganized.
Terminal differentiation did not appear to be affected, as mRNA expression of myogenic
regulatory genes such as myoD, myogenin, MRF-4, and p21Cip was not different in the
homozygous knockouts compared to normal control littermates. The authors
commented that the skeletal muscle phenotype is closest to a myogenin mutation
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where secondary myogenesis is disrupted. However, they hypothesized that Ski may
help to regulate the balance between proliferation, terminal differentiation, and survival
of both skeletal muscle and neural lineages. The homozygous knockouts also had
skeletal abnormalities including malformed and undersized or absent bones. The defects
to the vertebrae represented a phenocopy of a Hox4 mutation. Another observation in
this study was that there was increased apoptosis in the cranial mesenchyme and the
cranial neural tube and that the timing of the apoptosis occurs at the same time as the
neural tube should be closing in normal mice. Normal mice also showed high expression
of Ski mRNA in these areas at this time in development.
A follow-up study examined the effect that the strain of mouse has on the
phenotype of the Ski knockout (Colmenares et al., 2002). This study examined 129P2
and Swiss black backcrosses, and 129P2 and C57BL/6 backcrosses. Homozygous
knockouts that were backcrossed on a 129 background were much more likely to have
exencephaly than a facial cleft. Conversely, homozygous knockout mice backcrossed on
a C57BL background were more likely to have a facial cleft than exencephaly. In both
cases only a small percentage of the homozygous knockouts showed no craniofacial
defects. The percentages of different phenotypes that were obtained from additional
intercrosses indicate that a complex expression system consisting of several modifier
genes was involved rather than a single modifier.
Another study looked at ocular abnormalities in a Ski knockout mouse
(McGannon et al., 2006). They found that 100% of the homozygous negative mice had
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persistent hyperplastic primary vitreous (PHPV). This is a defect in ocular development
where fetal vitreous tissue and vasculature involute. The etiology of PGPV is not well
defined, but there is some evidence that abnormal retinoic acid signaling may be
involved. The mice also showed other eye abnormalities including anterior segment and
lens dysgenesis, retinal folds, chorioretinal coloboma, and Peters anomaly. This
phenotype resembles that of animals lacking retinoic acid receptor genes, or animals
exposed to excess retinoic acid during gestation. The authors hypothesized that this
phenotype may be due to Ski’s interaction with retinoic acid receptors.
There is one Ski knockdown study where a novel vector was used to express a
long double-stranded RNA from an RNA polymerase II promoter (Shinagawa and Ishii,
2003). This method generates transcripts that lack a 5’-cap structure and a 3’-poly(A)
tail, facilitating transport to the cytoplasm and leading to a more robust siRNA response
with decreased likelihood of an interferon response. Embryos from C57BL mice were
used in this study and defects in neural tube closure and eye formation that are
phenotypic of Ski homozygous knockouts were found in the mice.
A condition known as 1p36 monosomy is a rare disorder in humans where the
end of one of chromosome 1 is missing. The missing region contains, among other
genes, the SKI gene. This deletion syndrome is associated with cleft lip and/or
cleft palate, large anterior fontanelle, hypotonia, moderate to severe mental
retardation, seizures, growth delay, pointed chin, eye and vision problems, deep-set
eyes, hearing deficits, low-set ears, clinodactyly, flat nasal bridge, abusive behavior,
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and thickened ear helices. Specific eye and vision abnormalities found in 1p36 deletion
syndrome are strabismus, sixth-nerve palsy, amblyopia, hyperopia, myopia, astigmatism,
anomalous optic disks, and lacrimal defects. Unlike the mouse knockout studies, this
condition is a heterozygous loss and is complicated by the loss of other genes.
Nevertheless, some of the same symptoms that are present have been found in the
mouse knockouts.
The developmental defects seen in the Ski knockout mice may be partially
explained by Ski’s interaction with the bone morphogenetic protein (BMP) pathway.
BMP receptors are members of the TGFβ family. They signal via Smad proteins and their
signaling can be modified by Ski (Luo, 2003). Ski has been shown to modify the
expression of two BMP responsive genes, Vent1/2 is repressed and NCAM is induced by
Ski overexpression (Wang et al., 2000). Vent1/2 are important in ventral patterning in
Xenopus laevis (Wang et al., 2000), while NCAM is a neural specific adhesion protein
that is important in neurodevelopment (Paratcha and Ledda, 2008).
The expression pattern of Ski in mice shows correlations between the pattern
and the proposed function of Ski (Lyons et al., 1994; Namciu et al., 1995). The first large
increase in Ski expression occurs at the time of neural tube closure and migration of
neural crest cells. The second large increase in Ski expression correlates with skeletal
muscle development. Additional evidence of Ski’s function in neural development was
found when Ski mRNA was injected into endodermal cells in Xenopus laevis embryos,
and an ectopic neural tube-like structure formed (Amaravadi et al., 1997). Cells derived
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from the injected cells were found in the spinal cord. These data provide more
supporting evidence for Ski’s role in neural development.
SnoN also appears to be important in at least some developmental pathways.
One line of SnoN homozygous knockout mice are embryonic lethal and die before
implantation (Shinagawa et al., 2000). Analysis indicates that they fail to continue
beyond the 16-cell stage and do not develop normal blastocysts. It is clear from this
work and the work on Ski knockouts that Ski and SnoN have different functions in
development. Heterozygous SnoN knockouts appeared healthy at birth, but displayed
severe wasting after 4 months. These mice also developed spontaneous lymphomas and
an increased frequency of tumors relative to normal mice when challenged with a
carcinogen. There is a decreased sensitivity to apoptosis and cell cycle arrest in B cells, T
cells, and fibroblasts of these mice as well. These data indicate that SnoN also acts as a
tumor suppressor. Two other lines of SnoN homozygous knockout mice were found to
be viable and only showed defects in T cell activation (Pearson-White and McDuffie,
2003). These defects could be overcome by incubation with either anti-TGFβ antibodies
or exogenous interleukin-2. It is not clear why there is a discrepancy between the two
studies.
There is growing evidence that Ski also has a role in hematopoiesis (Beug et al.,
1995; Dahl et al., 1998a; Larsen et al., 1993; Namciu et al., 1994; Pearson-White et al.,
1995; Ueki et al., 2008). The first indication of this role was the ability of v-ski and either
ts-v-sea or c-kit to transform myeloid cells that arise either from the monocyte and/or
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granulocyte lineages or erythroid cells (Larsen et al., 1993). The cells did not display a
transformed phenotype when v-ski was transfected into the cells without one of the
other genes. This data led to studies examining the long-term effect of v-ski and c-kit
expression in primary avian multipotent progenitors (Beug et al., 1995). The cells were
immortalized and had a life span of over 100 generations. Further examination of the
immortalized cells showed that Ski associates with the retinoic acid receptor (RAR)
complex and can act as a repressor of a retinoic acid response element (Dahl et al.,
1998a). Using high concentrations of RARα-specific ligand they were able to abolish the
v-ski mediated transformation of the multipotent progenitors. Ski mRNA expression was
also found to be upregulated in myeloid cell lines that were exposed to phorbol 12myristate 13-acetate (PMA) (Namciu et al., 1994). This study showed that Ski mRNA
levels only increase in the cell lines that respond by differentiating along the
megakaryocyte lineage and that the increase is proportional to the concentration of
PMA used. An extensive study of both Ski and Sno mRNA expression was performed in
hemolymphopoietic linages (Pearson-White et al., 1995). The researchers found that the
two proteins are differentially expressed with Sno being expressed more widely in
myeloid

progenitors

and

Ski

being

expressed

in

dual-linage

megakaryocyte/erythrocytes. Another protein that interacts with Ski is the transcription
factor PU.1, which is a myeloid and B-cell specific E26 transformation specific (ETS)
family member (Ueki et al., 2008). Ski recruits histone deacetylase 3 to PU.1-occupied
promoters, blocking transcription activation and subsequent differentiation into
macrophage colony-stimulating factor receptor (M-SCFR)-positive macrophages. It is
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evident from these studies that the functions of Ski and SnoN in hematopoiesis are
beginning to be elucidated. More work is still needed to clarify the distinct roles of each
in this developmental process.
1.3.5 Cancer
Ski and SnoN were first posited to be involved in oncogenesis because of their
transforming abilities in chicken embryo and quail embryo cells (Li et al., 1986).
Originally, SKI was incorrectly mapped to the region of 1q22-q24 and implicated in
several different cancers with chromosome abnormalities in that region. It has been
reported that non-Hodgkin’s lymphomas often have chromosomal translocations
involving this region (Chaganti et al., 1986). SKI was also associated with Merkel cell
carcinoma, in which 89% of the tumor samples examined showed chromosomal
abnormalities

(Koduru et al., 1989). Many of the samples had chromosomal

rearrangements in the region of 1q22. Another chromosome 1 translocation that was
found in a case of pre-B acute lymphoblastic leukemia (ALL) was thought to involve SKI
because of the 1q23 mapping of the translocation (Kees et al., 1990). Finally, another
study examined a ganglioneuroblastoma patient with a t(1;13)(q22;q12) translocation
(Michalski et al., 1992). All of these studies only performed chromosome analysis and
did not look at either gene expression or protein quantification. No mutations were
found in the SKI gene in any of these studies.
Melanoma is the sixth most common cancer in the U.S. and has the worst
prognosis of any of the skin cancers (Jemal et al., 2008). Ski was examined in six
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melanoma cell lines and normal melanocytes. No mutations in the SKI gene were
detected but Ski mRNA was expressed at a higher level in melanoma cell lines than in
normal melanocytes (Fumagalli et al., 1993). Further inspection of the Ski protein in
melanoma led to the finding that Ski is predominately nuclear in preinvasive
melanomas, but present in both the nucleus and the cytoplasm of primary invasive and
metastatic melanoma tumors (Reed et al., 2001). The importance of Ski in melanomas
was then ascertained by using an antisense Ski vector to knock down the high
endogenous Ski expression in melanoma cell lines, restoring TGFβ mediated growth
inhibition. Ski has been previously shown before to interact with activated Smad
complexes in the nucleus and repress Smad mediated TGFβ signaling (Luo et al., 1999).
In melanoma, Ski interacts with Smad3 in the cytoplasm and prevents its nuclear
transport. Blocking Smad nuclear transport effectively inhibits Smad-mediated TFGβ
signaling in the cytoplasm (Reed et al., 2001). These data suggest that the inhibition is
mediated by the up-regulation of cyclin-dependent kinase inhibitor p21 (Waf-1) and
inhibition of cyclin-dependent kinase 2 activity is due to high levels of Ski. It was then
discovered that Ski activates the Wnt/beta catenin signaling pathway, presumably
through its interaction with the transcription factor FHL2 (Chen et al., 2003). Gene
targets of this interaction include microphthalmia-associated transcription factor and
Nr-CAM. These proteins are associated with melanoma cell survival, growth, motility,
and transformation.
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SnoN has also been found to be highly expressed at both the mRNA and the
protein levels in melanoma cell lines (Poser et al., 2005). However, only one of the cell
lines examined was positive for Ski expression. A stable cell line was generated
expressing an antisense SnoN vector in one of the Ski-negative cell lines. This cell line
demonstrated reduced proliferation, indicating that high SnoN expression was making
the cells unresponsive to TGFβ mediated growth inhibition. Unlike Ski, data indicate that
SnoN does not regulate p21 expression. However, a target gene of TGFβ, the
transcription factor Id1, is repressed by SnoN. These results indicate that, although both
Ski and SnoN are involved in melanoma progression, they may exert this influence by
different mechanisms.
There is growing evidence that Ski and SnoN may be involved in the progression
of esophageal squamous cell carcinoma (ESCC). Ski protein levels in 80 surgical samples
and 6 cell lines were examined by immunohistochemistry and Western blotting and
compared to normal epithelium and an immortalized esophageal keratinocyte cell line
(Fukuchi et al., 2004). Although SnoN expression was not significantly correlated with
any of the clinicopathological characteristics of the patient samples, Ski showed
significant correlation with depth of invasion, pathological stage, and TGFβ expression.
Five of the six cell lines had high Ski expression and concomitant low expression of p21,
which was hypothesized to be caused by Ski’s repression of TGFβ signaling. Support for
the involvement of SnoN in the progression of esophageal cancer was demonstrated in
studies involving a growth inhibition-resistant esophageal cancer cell line. It was found
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that SnoN forms complexes with Smad3 in the cell lines that lack TGFβ signaling
(Edmiston et al., 2005). This result can be explained by subsequent research that
showed that the cell line that was used had lost the E3 ubiquitin ligase Arkadia (Levy et
al., 2007). This protein marks SnoN for degradation only when Arkadia is in a complex
with activated Smad2 or Smad3; thus, Arkadia downregulates SnoN upon Smadmediated TGFβ signaling. In the absence of Arkadia, SnoN represses c-myc transcription,
preventing growth arrest and leading to oncogenesis.
A recent study examined SnoN protein levels by immunohistochemistry in 59
ESCC patient samples and found higher levels of SnoN in primary ESCC compared to
corresponding normal epithelia (Akagi et al., 2008). The protein levels had significant
correlation with depth of invasion and recurrence. In addition, 52.5% of the samples
were positive for SnoN and the positive samples were correlated with more unfavorable
outcomes. A common amplification in these samples at 3q26, the approximate
chromosomal location of SKIL, is thought to be responsible for the high levels of SnoN in
these cases.
Another recent study examined the protein levels of Ski and SnoN by
immunohistochemistry in patients with Barrett’s esophagus (BE) and found that,
although neither protein was expressed in normal esophageal epithelium, both were
strongly expressed in BE (Villanacci et al., 2008). The positive samples displayed
cytoplasmic staining, a decrease of staining in dysplastic areas in patients with low-
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grade dysplasia, and an absence of staining in patients with high-grade dysplasia or highgrade dysplasia/adenocarcinoma.
Chronic myelogenous leukemia (CML) is a myeloproliferative disorder
characterized by t(9;22), known as the Philadelphia Chromosome. This translocation
produces the Bcr-Abl fusion protein and leads to excessive neutrophil production. In one
study looking at Ski in CML, Ski was one of 158 genes that were significantly
overexpressed in CML CD34(+) versus normal CD34(+) cells when examined using a
cDNA array and verified with real-time RT-PCR (Kronenwett et al., 2005). The
significance of this finding was discussed in the context of studies looking at Ski in
hematopoiesis, where myeloid cells transformed with v-ski and c-kit were immortalized
(Dahl et al., 1998a). The researchers propose that repression of the RAR signaling
pathway by Ski may be responsible for the oncogenic progression and that Ski should be
considered as a potential therapeutic target in CML.
In the United States, colorectal cancer is the third most common cancer among
both men and women (SEER). Both incidence and mortality rates have been slowly
decreasing over the last twenty years, with decreases of 2.6% and 4.4%, respectively. Ski
was examined in the context of colorectal cancer and amplification of the SKI gene was
found to be a negative prognostic marker in early colorectal cancer (Buess et al., 2004).
However, deletion of neither of the SKI nor SKIL genes was correlated with cancer
progression.
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Rhabdomyosarcoma (RMS) is predominately a childhood cancer and the most
common soft tissue cancer in children under 14, with an incidence rate of 4.6 cases per
million (Loeb et al., 2008). RMS is classified into two major groups by histology,
embryonal (eRMS) and alveolar (aRMS). eRMS histologically resembles immature
skeletal muscle, while aRMS resembles normal lung parenchyma. The alveolar subtype
has chromosome translocations in over 75% of cases, resulting in either t(2;13)(q35;q14)
with the PAX 3/FKHR fusion protein or t(1;13)(p36;q14) with the PAX 7 /FKHR fusion
protein (Loeb et al., 2008). The later translocation results in a break in the region of the
SKI gene which is located at 1p36.3. Both varieties have been found to express muscle
specific markers such as desmin and MyoD (Loeb et al., 2008). There is scant data
concerning involvement of Ski and/or SnoN in RMS. An early study looking at Ski and
SnoN expression in a variety of cell lines found that Ski mRNA is expressed in the eRMS
cell line named RD (Colmenares and Stavnezer, 1990). Another paper reported the
discovery of a novel SnoN splicing variant, SnoI, and the expression of its mRNA in RMS
tissue (Pearson-White, 1993). The only other mention of Ski in RMS is from a study of
PATCHED1 mutant mice in which heterozygous knockouts develop medulloblastoma
and RMS (Eichenmuller et al., 2007). These mice showed an increased level of
transcription of a number of genes including Ski and TGFβ. Although there has been
little research into the involvement of Ski and SnoN in RMS, I believe that there may be
a functional link. RMS is a cancer in which many of the cells express myogenic factors
and structural skeletal muscle proteins. As both Ski and SnoN have been shown to have
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involvement in not only a growing list of different cancers but also in myogenesis, it
would seem likely that they would be involved in RMS.
The mechanism(s) of Ski’s and SnoN’s contribution to oncogenesis is not clear. As
mentioned previously, some of the pathways involved are beginning to be deciphered.
One of the interactions that may be important is the repression of the transcription
factor c-Myb (Nomura et al., 2004). c-Myb has been associated with both myeloid
leukemia and cysplatin resistance in colon cancer (Funato et al., 2001; Jahagirdar et al.,
2001). Another protein-protein interaction that may be involved is the interaction of Ski
with pRb. Overexpression of Ski has been shown to lead to hyperphosphorylation of pRb
and cellular proliferation (Jacob et al., 2008). Ski and pRB are then colocalized in the
cytoplasm. Overexpression of Ski and SnoN may also lead to low affinity interactions
that would not otherwise occur and produce oncogenic effets. TGFβ signaling
suppresses the ability of Ski to inhibit tumor metastasis by inducing Ski’s degradation
through a complex formed with phospho-Smad2 or Smad3 and Arkadia (Le Scolan et al.,
2008). Therefore, the loss of either TGFβ signaling or Arkadia will inhibit Ski degradation
and will lead to the deregulation of Ski. As mentioned in the context of melanoma, the
interaction of Ski with the Wnt/β-catenin signaling pathway may also prove to be
important in tumor progression. Since the inactivation of this pathway is common in
colorectal cancers, it was hypothesized that this may be a mechanism of Ski’s function in
colorectal cancer (Buess et al., 2004). Data also supports the function of Ski and SnoN as
tumor suppressors. Both Ski and Sno heterozygous mouse knockouts have an increased
35

susceptibility to tumorigenesis (Shinagawa et al., 2000; Shinagawa et al., 2001). Based
on the studies summarized above, it is apparent that Ski and SnoN have a role in
oncogenesis; however, more data is needed to determine how they are involved and if
they are a viable therapeutic target in specific cancers.

1.4 Hypothesis & Approaches
Ski and SnoN are important in several aspects of development including
myogenesis. Knockouts of either gene led to developmental defects in heterozygous
models and lethality in double knockouts. Animal models overexpressing Ski or SnoN
demonstrate muscle hypertrophy and muscle weakness. Knockouts of these genes do
not have myogenic defects, although it is possible that one can compensate for the loss
of the other. It is also apparent that Ski and SnoN overexpression and/or mislocalization
is found in many types of cancer. This information led me to investigate the mechanism
of Ski localization and the possible involvement of Ski and SnoN in a cancer with skeletal
muscle characteristics, RMS.
My first hypothesis is that Ski contains a functional nuclear localization signal
(NLS) that is both necessary and sufficient for nuclear localization. Recent studies have
shown that, in some cancers, Ski is located in the cytoplasm in addition to its normal
nuclear location. Defining the NLS will aid in further research into this mislocalization. In
order to obtain putative candidates for an NLS, we used computer algorithms to find
likely sequences. I then used a combination of site-directed mutagenesis and restriction
enzymes to create plasmids with green fluorescence protein (GFP) fused to various
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mutants of Ski. These fusion proteins were expressed in a variety of cell lines and the
subcellular localization of the fusion protein was monitored by fluorescence microscopy.
I determined that when a putative NLS predicted by my computer analysis to be similar
to the SV40 large T antigen was mutated by in vitro mutagenesis, Ski was located almost
exclusively in the cytoplasm. I also discovered that when the non-mutated NLS is fused
to GFP it is located mostly in the nucleus. However, the mutated NLS fused to GFP was
found almost exclusively in the cytoplasm. These results show that this NLS is sufficient
and necessary for Ski to localize to the nucleus.
My second hypothesis is that Ski and SnoN expression is prognostic in the
pediatric cancer RMS. Because Ski and SnoN are involved in myogenesis, and RMS
tumors exhibit skeletal muscle markers, I posit that they may be involved in the
pathogenesis of RMS. We examined both gene expression by real-time RT-PCR and
protein levels in cell lines derived from the RMS and in tumor tissue samples. I also used
immunofluorescence microscopy to determine the quantity location of Ski and SnoN in
the tumor samples. I found a large variation in the subcellular localization of Ski and
SnoN in the cancer cell lines. I did not see any correlation between the localization of
the proteins with the expression levels in the rhabdomyosarcoma cell lines. However,
my data do show that Ski protein level in rhabdomyosarcoma tumor tissue is negatively
correlated with tumor group.
My third hypothesis is that Ski phosphorylation is specific to its subcellular
location. There are several reports of Ski being phosphorylated and it is believed that
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this modification could be responsible for regulating subcellular localization. I used
subcellular fractionation, immunoprecipitation, and Western blotting to determine the
location of phosphorylated Ski. My data show that Ski is phosphorylated when it is
localized to the cytoplasm, but Ski is unphosphorylated in the nucleus.
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Chapter 2: Characterization of the Nuclear Localization Signal in
Ski
2.1 Abstract
Ski is a transcription factor that acts as a co-repressor of the Smad-mediated
transforming growth factor beta (TGFβ) signaling pathway. Ski is usually found in the
nucleus where it can recruit histone deactylaces (HDACs) and form complexes with
activated Smad proteins on Smad binding elements within promoters on DNA. Data
from Ski knockout and overexpression experiments indicate that Ski may have other
functions as well. In metastatic melanoma, Ski is located in both the nucleus and the
cytoplasm in contrast to its normal nuclear localization. Under the assumption that the
mechanism of Ski subcellular localization is important in the progression of melanoma,
we decided to look into how this is regulated. Our hypothesis is that the putative NLS is
an SV-40 large T antigen-like sequence and that Ski localization is determined by
phosphorylation state. We have found that Ski has a functional nuclear localization
signal (NLS) that is sufficient and necessary for Ski to localize to the nucleus. This finding
has been confirmed by another paper using a different mutagenesis strategy. We have
also found that serine phosphorylated Ski is only found in the cytoplasm.

2.2 Background
Proteins are often localized to specific subcellular compartments to carry out
their normal function. This localization often requires specific sequences that are
recognized by transport proteins. An example is the nuclear localization of the simian
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virus 40 (SV40) large T antigen via karyopherin proteins and the RAN GTPase system.
The SV40 large T antigen contains a nuclear localization sequence or NLS (PKKKRKV) that
has been shown to be necessary and sufficient for localization to the nucleus (Smith et
al., 1985). This SV40 NLS or related sequences have been shown to interact with the
karyopherin importin α (Yoneda et al., 1999). The SV40-bound importin α then binds to
importin β, which facilitates translocation into the nucleus via interactions with
nucleoporins within the nuclear pore complex. Another class of NLS contains a bipartite
signal (Boulikas, 1993), which consists of two clusters of basic amino acids that are
usually separated by a spacer of around 10 amino acids. Importin α also interacts with
the bipartite NLS. We used an NLS prediction computer algorithm to search for a
putative NLS in Ski. The algorithm identified both an SV40 large T antigen-like NLS and a
bipartite signal. We investigated both of these and have determined that only the SV40like NLS appears to be functional.

2.3 Methods
2.3.1 Antibodies
The antibody to SnoN was purchased from Cell Signaling Technology (cat. #4973,
Danvers, MA) and used at dilution of 1:200. The phosphoserine antibody was purchased
from Abcam (cat. #ab9332, Cambridge, MA) and used at a dilution of 1:500 for Western
blots and 10µl per 80 µl of cellular extract for IPs. The anti-Ski antibody is a rabbit
polyclonal generated against the peptide CRVSSEPPASIRPKTDDTSS. Both the peptide
and the antibody were purchased from New England Peptide (Gardner, MA). The
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antibody was purified by affinity chromatography by the manufacturer. The antibody
was used at a dilution of 1:250 for IF, 1:1000 for Western blots, and 10µl per 80 µl of
cellular extract for IPs. Secondary antibodies were purchased from Jackson
ImmunoResearch (West Grove, PA) and used at a dilution of 1:250 for IF and 1:5000 for
Western blots.
2.3.2 Cell Culture and Transfection
HeLa or SJRH30 rhabdomyosarcoma cells were obtained from ATCC (Manassa, VA) and
were cultured in DMEM (cat. #12430-104, Gibco, Carlsbad, CA) with 10% FBS (cat.
#16140-071 , Gibco, Carlsbad, CA) 100U/ml Penicillin and 100µg/ml Streptomycin (cat.
#15140-122, Gibco, Carlsbad, CA). Low passage number cells were seeded on 22mm
coverslips, allowed to attach and grow for 24hrs, and then transfected using Fugene6
(cat. #1814443, Roche, Basel, CN) according to the manufacturer’s directions.
2.3.3 Mutagenesis and Plasmid Construction
SKI was cloned from HeLa cells into pGEM-T Easy (cat. #A1380, Promega, Madison, WI)
using the following primers:
5’-AACTGGAGCATGGAGGCGGCGGCAGGCGGC-3’and
5’-AAGGATCCCGGCTCCAGCTCCGCAGCGCC-3’
The SKI gene was then cloned into the EGFP-N3 plasmid (cat. # 6080-1, Clontech, Palo
Alto, CA) by digesting both plasmids with XhoI and BamHI, gel purifying the fragments,
and ligating the Ski fragment into the GFP plasmid.
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The putative SV-40 large T antigen-like NLS of SKI was mutated by using PCR to mutate a
lysine to an alanine in the Ski-GFP plasmid. The mutation was generated with the first
round of PCR using the following primers pairs and Ski-GFP plasmid as the template:
5’-TGGCCGGCTCTTCCAATA-3’
5’-CTGGGTGCAAGTGGCGAGAGGCTCGGGGGCCCGGGAGAC-3’
and
5’-CTCGCCACTTGCACCCAGGTGGACACCCCAGGAGCCCCA-3’
5’-AGCTCCTCCACCACCTTCTC-3’
The two overlapping fragments were combined by using them as a template and
amplifying with the flanking primers. The resulting full-size fragment was cloned into a
Ski-GFP plasmid that had been digested with EcoRI enzyme to remove the
corresponding unmutated sequence.
The Ski-GFP 1-490 was constructed by digesting the Ski-GFP plasmid with XhoI and EcoRI
and gel purified the fragment. The EGFP-C2 (cat. # 6083-1, Clontech, Palo Alto, CA)
plasmid was digested with XhoI and EcoRI and the Ski fragment (1-490) was ligated into
the EGFP-C2 plasmid creating the Ski (1-490)-GFP plasmid.
To create the GFP-NLS-GFP and GFP-NLS-SDM-GFP constructs we digested EGFP-N3 with
NhoI and BamHI removing the MSC from the plasmid. EGFP-C3 (cat. # 6082-1, Clontech,
Palo Alto, CA) was digested with XhoI and EcoRI to prepare the plasmid for the NLS
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sequence. Both fragments were gel purified. The following single stranded nucleotide
sequences were designed for the NLS and NLS-SMD constructs:
5’-TCGAACCTCGGAAGCGGAAGCTGACTGTC-3’
5’-AATTGACAGTCAGCTTCCGCTTCCGACGT-3’
5’- TCGAACCTCGGAAGCGGGCCCTGACTGTC-3’
5’-AATTGACAGTCAGGGCCCGCTTCCGACGT-3’
These were used to construct GFP-NLS-GFP and GFP-NLS-SDM-GFP, respectively. Each
pair was duplexed by combining them in equal molar amounts in STE buffer and heating
them to 95°C for 10min. They were then allowed to cool to room temperature for 1 hr.
A 5’phosphate was added to the duplex DNA by incubating the DNA in 2X rapid ligation
buffer with T4PNK at 37°C for 1hr. The DNA was gel purified and ligated to EGFP-C3. The
ligated plasmid was digested with NhoI and BamHI and gel purified. This fragment was
ligated into the digested EGFP-N3 plasmid which had been digested with the same
restriction enzymes. The resultant plasmid was electroporated into JM109 cells and
plasmid was purified using Qiagen Plasmid Maxi kit (cat. #12163, Qiagen, Valencia, CA).
All restriction enzymes were from New England Biolabs (Ipswich, MA) and all
oligonucleotides were ordered from Integrated DNA Technologies (Coralville, IA).
2.3.4 Immunofluorescence
Cells were grown on 22mm coverslips until nearly confluent. Cells were then fixed in 4%
formaldehyde in PBS for 20min and washed 3X in PBS. Cells were permeabilized in 0.4%
Triton X-100 in PBS with 1% NGS at 4°C for 5min and washed 3X in PBS with 1% NGS.
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The samples were then incubated for 1hr with primary antibody in PBS with 1% NGS and
then washed 3X in PBS with 1% NGS. The coverslips were incubated in the appropriate
fluorophore-conjugated secondary antibody for 1hr in PBS with 1% NGS, washed 4X in
HEPES Buffered Saline, mounted with Vectashield containing DAPI (cat. #H-1200, Vector
Laboratories, Burlingame, CA), and sealed with nail polish. Images were acquired with a
CoolSNAP HQ camera (Photometrics, Tucson, AZ) on a Zeiss Axioplan2 (Thornwood, NY)
using a Xenon light source and 63X (Plan-Apo, 1.4 NA) lens with Slidebook software
Version 4.2 (Intelligent Imaging Innovations, Denver, CO).
2.3.5 Protein Extraction
Cells were grown to near confluence in 75cm2 flasks and washed with PBS and detached
using trypsin-EDTA. FBS was added to inactivate the trypsin and the cells were pelleted
by centrifugation and washed with PBS. Cytoplasmic and nuclear proteins were
obtained using the NE-PER (cat. #78833, Pierce, Rockford, IL) kit according to the
manufacturer’s instructions. HALT phosphatase inhibitor (cat. #78420, Pierce, Rockford,
IL) and Complete Mini Protease Inhibitor Cocktail tablets (cat. #11836170001, Roche,
Basel, CH) were used according to the manufacturer’s directions.
2.3.6 Immunoprecipitation
40µl of EZview Red Protein A Affinity Gel (cat #P6486, Sigma, St. Louis, MO) was washed
3 times in the appropriate final nuclear or cytoplasmic buffer from the NE-PER kit. 80µl
of protein extract (see previous section) was added to the washed beads to pre-clear
the extracts of non-specific binding proteins, and incubated at 4°C for 1hr on a rocking
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platform. The samples were centrifuged and the extract was transferred to a tube
containing 10µl of either anti-Ski or anti-phosphoserine, and incubated at 4°C for 1hr on
a rocking platform. Then 80µl of fresh washed EZview Gel was added to each sample
and incubated at 4°C overnight on a rocking platform. The samples were centrifuged
and the EZview Gel was washed 3X in the corresponding final buffer from the NE-PER
kit. After the final wash, 100µl of Laemmli buffer (Bio-Rad, Hercules, CA) was added to
the gel, the samples were vortexed, snap frozen in liquid nitrogen and stored at -80°C
until needed.
2.3.7 Protein Electrophoresis and Western Blots
Protein samples from the IP were boiled for 10min in Laemmli buffer (Bio-Rad, Hercules,
CA), 30µl was loaded per lane on a 7.5% Tris-HCl Criterion gel (cat. #345-0006, Bio-Rad,
Hercules, CA) and then eletrophoresed for 1 hour at 200V. The samples were
transferred to a PVDF membrane (cat. #88518, Pierce, Rockford, IL) using a Criterion
blot apparatus (Bio-Rad, Hercules, CA) with Towbin buffer containing 10% methanol at
100V for 1.25hrs using pre-chilled reagents and a gel ice block inside the blot apparatus.
The blot was then blocked in TBS with 3% BSA (cat. #A2153, Sigma, St. Louis, MO) and
0.1% gelatin for 1hr. After washing the blot 3X in TBST (TBS with 0.1% Tween-20), it was
incubated overnight in primary antibody in TBST with 0.5% BSA at 4°C. The blot was
washed 3X in TBST and incubated 1hr in HRP-conjugated secondary antibody in TBST.
The blot was washed 3X in TBST and Pierce ECL Western Blotting Substrate (cat. #32106,
Pierce, Rockford, IL) applied according to the manufacturer’s directions. The blots were
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then exposed to BioMax MR film (Kodak, New Haven, CT) and developed in a film
developer.

2.4 Results
2.4.1 GFP Studies
Various GFP-Ski fusion constructs were generated to examine the function of a
putative NLS in Ski. For initial studies we created a Ski-GFP fusion construct using the
Clontech Living Colors GFP plasmid, which is under control of the CMV promoter, and
examined its location in different cell lines. The fusion protein was predominately
nuclear in all of the cells, with none of the cells having the fusion protein excluded from
the nucleus (see Figure 7, A & B). We next examined the construct that contained only
the N-terminal 490 amino acids of Ski fused to GFP (Ski-GFP 1-490). This construct
contains the putative SV40 NLS and was also predominately nuclear, although the
punctate staining pattern in the nucleus was different than that of the full size Ski-GFP
fusion protein (see Figure 7, C & D). The construct with the K454A mutation within the
putative NLS (Ski-GFP K454A) demonstrated nuclear exclusion in most of the cells,
indicating that the NLS was disrupted (see Figure 7, E & F). To confirm this result, we
generated GFP fusion constructs using the NLS fused to 2 copies of GFP to ensure that
the resulting fusion protein was large enough to prevent easy diffusion out of the
nucleus. The distribution of the GFP-NLS-GFP fusion protein was similar to that of the
Ski-GFP fusion protein, localizing predominately to the nucleus (see Figure 8, C & D).
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However, an NLS that had the K454A mutation fused to two copies of GFP (GFP-NLSSDM-GFP) localized predominately to the cytoplasm (see Figure 8, E & F).

Figure 7: Representative images of the Ski-GFP fusion protein, alone on the left and with a DAPI overlay
on the right. A & B are full-length Ski-GFP. C & D are Ski (1-490)-GFP containing the N-terminal 490 amino acids and
the SV40-like NLS. E & F are Ski-SDM-GFP with the full-length Ski and a site-directed mutation in the SV40-like NLS.
All images shown are SJRH30 cells.
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Figure 8: Representative images of the GFP fusion protein, alone on the left and with a DAPI overlay on
the right. A & B are GFP-GFP. C & D are GFP-NLS-GFP containing the SV40-like NLS from Ski. E & F are GFP-NLSSDM-GFP containing the SV40-like NLS from Ski with a site-directed mutation. All images shown are SJRH30 cells.
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2.4.2 Phosphorylation Studies
We next examined the phosphorylation status of nuclear and cytoplasmic Ski.
We obtained nuclear and cytoplasmic fractions of the SJRH30 rhabdomyosarcoma cell
line, immunoprecipitated with an anti-Ski antibody, and electrophoresed the resultant
protein fractions. After transfer to a PVDF membrane, the membrane was probed with
an antibody against phosphorylated serine. This produced a band in the cytoplasmic
fraction with an approximate molecular weight of 98kDa (Figure 9). The blot was
stripped and reprobed with an anti-Ski antibody and the same cytoplasmic band was
detected. To confirm this result we repeated the experiment using the antibody to
phosphorylated serine for the IP and the antibody to Ski to probe the blot. We found the
same molecular weight band in the cytoplasmic fraction. A control experiment for
assessing non-specific interactions was carried out using rabbit Ig G in the IP step and
anti-Ski antibody for the Western blot. No bands were detected in either the nuclear or
the cytoplasmic IP fractions (Figure 10).
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Figure 9: Western blots of lysates and IP eluates. The red arrows indicate the phosphoSki band. The data
indicate that Ski is phosphorelated in the cytoplasm but not in the nucleus.

Figure 10: Control Western Blost with Mouse IgG.
Homo sapiens
APPAQQKVVSSPPCAAAVSRAPEPLATCTQPRKRKLTVDTPGAPETLAPVAA
Equus caballus
APPAQQKVVSSPPCATVVSRAPEPLATCVQPRKRKLAVDTPGAPETPVPVAA
Mus musculus
APPTQQKVVNSPPCTTVVSRAPEPLTTCIQPRKRKLTLDTAGAPDMLTPVAA
Rattus norvegicus
APPTQQKVVNSPPCTTVVSRAPEPLTTCIQPRKRKLTMDAPGAPDMLTPVAA
Canis lupis familiaris
APPAQQKVVSSPPCATVVSRATEPLATCLQPRKRKLTVDTPGAPETPAPAAA
Macaca mulatta
APPAQQKVVSSPPCTAAVSRAPEPLATCTQPRKRKLTVDTPGAPETLAPVAA
Bos Taurus
APPAQHKAVSSPPCATVVSRAPEPLPACIQPRKRKLPADTPGAPETPAPGPA
Gallus gallus
APPAQQKVVSNPPCATVVSRSSEPPSSAAQPRKRKHAAETPAVPEPVATVTA
Monodelphis domestica
APPPQ-KIVSSPPCTTMVARAPEPLPTSIQPRKRKLPMETLGVPETLVPAAA
Xenopus laevis
TPPVQQKVITSPPCVPALPRSTQSSGSPPQSRKRRPTAELPIVPEAPAPPAP
Figure 11: Protein alignment of Ski in various species from Kalign at EMBL-EBI
(http://www.ebi.ac.uk/Tools/kalign/index.html). The NLS is colored red and the mutated arginine is colored green.
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2.5 Discussion
Our data support the hypothesis that the SV40 large T antigen-like Ski NLS is
necessary and sufficient for nuclear localization of Ski. This sequence is highly conserved
through evolution as can be seen in Figure 11. Insects have only one ortholog to Ski and
SnoN and this insect ortholog has less homology to either the mamalian Ski or SnoN
proteins than they have to each other (da Graca et al., 2004). The Drosophila
melanogaster SnoN protein does not contain the SV40-like NLS that we found in the
human Ski. This NLS is also not found in the human SnoN protein. In fact, an NLS was
recently discovered in the N-terminus of SnoN that is not conserved in the Ski protein
(Krakowski et al., 2005).
The data from the phosphorylation experiments suggest that phosphorylation
may also be important in Ski subcellular localization. Previous research suggest that Ski
is phosphorylated at certain times during

the cell cycle, although the specific

phosphorylation status appeared to vary in different cell lines (Marcelain and Hayman,
2005). This research also indicates that cdc2 (Cdk1) can phosphorylate Ski in vitro. In the
rhabdomyosarcoma cell line that we used, Ski was localized to both the nucleus and the
cytoplasm. This localization pattern is also found in other types of cancer such as
metastatic melanoma and esophageal squamous cell carcinoma (Fukuchi et al., 2004;
Reed et al., 2001). Cyclin-dependent kinases (Cdks) have been found to be frequently
mutated in cancers (Malumbres et al., 2003). It would be plausible that the cytoplasmic
localization of Ski is the result of a Cdk mutation or deregulation leading to
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phosphorylation of Ski and its subsequent cytoplasmic localization. Future studies will
be directed at determining the phosphorylation sites on Ski and their functions.
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Chapter 3: Protein Expression and Subcellular Localization of the
Oncoprotein Ski in Rhabdomyosarcoma
3.1 Abstract
Ski is a transcription factor that acts as a co-repressor of the Smad-mediated
TGFβ signaling pathway through its interaction with Smad complexes and histone
deacetylases. It has been reported that this normally nuclear protein is localized to both
the nucleus and the cytoplasm in metastatic melanoma and in esophageal squamous
cell carcinomas. In metastatic melanoma cell lines, Ski has been found to sequester
activated Smads while in the cytoplasm, preventing them from translocating to the
nucleus. Ski has been implicated in myogenis but has not been studied in
rhabdomyosarcoma (RMS), which is a cancer with characteristics of skeletal muscle. We
examined the location of Ski in several different cancer cell lines, in RMS tissue samples,
and in differentiating myoblasts. The RMS tumor group was found to be inversely
correlated with Ski protein intensity in the tissue samples. We also found a slight shift
towards Ski cytoplasmic localization in the differentiated myotubes, with discrete areas
of intense Ski staining. Fluorescence resonance energy transfer (FRET) was performed to
examine the co-localization and intracellular interaction of Ski with the Ski family
member SnoN. We detected FRET between Ski and SnoN in both the nucleus and the
cytoplasm.
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3.2 Introduction
The chicken homolog of Ski was the focus of early studies since the group at
Sloan Kettering Institute that discovered Ski was working with avian viruses and chicken
embryos (Barkas et al., 1986; Sutrave and Hughes, 1989). These studies found that when
the embryos were transfected with retroviruses expressing chicken Ski, the protein was
located in a speckled pattern in the nucleus while being excluded from the nucleolus
(Sutrave and Hughes, 1989). Ski was also found to associate with condensed chromatin
in mitotic cells. The idea of Ski being a nuclear protein was further reinforced when Ski
was found to act as a co-repressor of Smad-mediated TGFβ signaling by forming
complexes on DNA (Akiyoshi et al., 1999). Ski’s association with melanoma was
uncovered when Ski was found to be predominately nuclear in preinvasive melanomas,
but in both the nucleus and the cytoplasm of primary invasive and metastatic melanoma
(Reed et al., 2001). In addition, Ski has been found to be cytoplasmic in esophageal
squamous cell carcinoma (Fukuchi et al., 2004). Cytoplasmic Ski has subsequently been
found to be functional, sequestering activated Smad complexes in the cytoplasm, which
inhibits Smad-mediated TGFβ signaling (Reed et al., 2001). There is evidence that Ski
interacts with hyperphosphorylated pRb in the cytoplasm of Schwann cells and
influences cell proliferation (Jacob et al., 2008). RMS is a pediatric cancer with
characteristics of skeletal muscle. Early research showed that SKI and SKIL are expressed
in RMS tissue but their proteins have not been studied in this context. Ski and SnoN
increase the transcription of myogenin promoting skeletal muscle myogenesis so we
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thought that this would be an interesting cancer to examine (Deheuninck and Luo,
2009).
The Ski and SnoN proteins interact forming heterodimers and trimers that are
thought to be important for transcription regulation. This interaction was determined
when researchers immunoprecipitated them together from reticulocyte lysates in which
they had been overexpressed together (Nagase et al., 1993). These experiments were
done before Ski was found to be mislocalized in some cancers and so the subcellular
location of this interaction was not examined. We hypothesized that Ski and SnoN
interact in the cytoplasm when they are both in that subcellular location as seen in
some cancers. We used fluorescence resonance energy transfer (FRET) microscopy to
determine if Ski and SnoN interact in the nucleus or the cytoplasm.
FRET is a very sensitive tool that is useful in measuring protein-protein
interactions when the interacting proteins are within 10nm of each other. The more
important criteria are that the fluorophores involved should be within 10nm and in the
correct orientation to allow dipole-dipole coupling (Kenworthy, 2001). One method to
measure FRET is by directly exciting the donor fluorophore and measuring the
fluorescence emitted from the acceptor fluorophore. This method requires specific FRET
filter sets for the fluorescence microscope as well as software for acquisition and
mathematical FRET determination. We chose to use the acceptor photobleaching
method where images of the donor and acceptor are acquired before and after
photobleaching the acceptor (Kenworthy, 2001). The FRET is determined by measuring
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the increase in fluorescence of the donor. This occurs because energy transfer from the
donor to the acceptor that occurs in FRET results in quenching of the donor
fluorescence. When the acceptor is photobleached, the quenching is halted and the
energy from the donor that had been exciting the acceptor is now visible fluorescence.
The general equation to determine FRET efficiency is:

𝐸=

1
𝑟
1+ 𝑅
0

6

where E is the efficiency, r is the distance between the donor and acceptor, and R0 is the
distance between the donor and acceptor where FRET efficiency is 50% (Kenworthy,
2001). The equation used to determine the ratio of FRET in acceptor photobleaching is:

%𝐹𝑅𝐸𝑇 =

𝐼𝐷𝑜𝑛𝑜𝑟

𝑃𝑜𝑠𝑡𝐵𝑙𝑒𝑎𝑐𝑖 ℎ𝑛𝑔

𝐼𝐷𝑜𝑛𝑜𝑟

− 𝐼𝐷𝑜𝑛𝑜𝑟

𝑃𝑟𝑒𝐵𝑙𝑒𝑎𝑐 ℎ𝑖𝑛𝑔

𝑃𝑜𝑠𝑡𝐵𝑙𝑒𝑎𝑐 ℎ𝑖𝑛𝑔

× 100%

The variable “I” represents the individual pixel intensity (Stepensky, 2007). Although
most FRET experiments are performed by expressing fluorescently tagged proteins such
as cyan fluorescent protein (CFP) and yellow fluorescent protein (YFP) as the donor and
acceptor fluorophores, there have been reports of FRET experiments using endogenous
proteins labeled with Cy3 and Cy5-conjugated antibodies (Kenworthy, 2001). Our
preliminary studies expressing Ski-GFP proteins in cell lines indicated that the fusion
protein did not match the endogenous localization, with the fusion protein being mostly
nuclear in cell lines that had cytoplasmic expression of endogenous Ski. In order to
obtain what we believe to be the most accurate in vivo result we decided to use
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antibodies to visualize interactions between the endogenous proteins instead of GFP
fusion proteins.
Ski and SnoN were close enough to produce FRET in both compartments
although we detected a higher prevalence of FRET in the cytoplasm than in the nucleus.
This would mean that they are within 10nm of each other and in an orientation that
would allow for efficient FRET. We also looked at Ski protein level and localization in
cancer cell lines, rhabdomyosarcoma (RMS) tumor tissue, and differentiating myoblasts
to determine the localization of Ski in these samples and found that the localization
varied among the cell lines and increased slightly during myogenesis. The data with the
RMS tumor tissue indicate that Ski protein level has a significant negative correlation
with RMS tumor group.

3.3 Methods
3.3.1 Antibodies
The antibody to SnoN (#4973) was purchased from Cell Signaling Technology (Beverly,
MA) and used at a dilution of 1:100 for paraffin sections and 1:200 for cell lines. The
antibody

to

Ski

is

a

rabbit

polyclonal

generated

against

the

peptide

CRVSSEPPASIRPKTDDTSS. Both the peptide and the antibody were custom made by New
England Peptide (Gardner, MA). The antibody was used at a dilution of 1:250 in cell
lines. For FRET studies the Ski antibody was covalently linked to Cy5 using the
Amersham (Chalfont St. Giles, UK) Cy5 antibody labeling kit (PA3500). In paraffin
sections the antibody was used at a dilution of 1:100 and in cell lines it was used at a
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dilution of 1:150. Secondary antibodies were purchased from Jackson ImmunoResearch
(West Grove, PA) and used at a dilution of 1:250.
3.3.2 Cell lines and Cell Culture
HeLa, SJRH30, RD, HS729t, A204, and A673 cell lines were purchased from ATCC
(Manassas, VA). RMZ-RC2 cells were kindly provided by Drs. Lorena Landuzzi and PierLuigi Lollini at the Laboratory of Immunology and Biology of Metastasis, Cancer
Research Section, Department of Experimental Pathology in Bologna Italy. MCF-7 and
MDA-MB-231 cells were kindly provided by Dr. Rebecca Hartley at the UNM HSC. LNCaP
cells were kindly provided by Dr. Marco Bisoffi at the UNM HSC. HSMM cells were
purchased from Cambrex (Walkersville, MD).
HeLa, SJRH30, RMZ-RC2, RD, HS729t, A204, A673 LNCaP, and MCF-7 cells were cultured
in DMEM (cat. #12430-104, Gibco, Carlsbad, CA) with 10% FBS (cat. #16140-071, Gibco)
and 100U/ml Penicillin and 100µg/ml Streptomycin (cat. #15140-122, Gibco). Clonetics
HSMM cells were grown in Sk-GM-2 media (cat. #CC-3245, Cambrex, Walkersville, MD).
HSMM cells were differentiated in DMEM with 2% horse serum (cat. #26050-070, Gibco)
and 100U/ml Penicillin and 100µg/ml Streptomycin. MDA-MB-231 cells were cultured in
DMEM/F12 (cat. #11320-082, Gibco) with 10% FBS and 100U/ml Penicillin and 100µg/ml
Streptomycin. Low passage number cells of each cell line were seeded on #1.5 22mm
coverslips, allowed to attach and grown until nearly confluent.
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3.3.3 Tumor Tissue
The RMS tumor samples were acquired from the Cooperative Human Tissue Network
(CHTN) at the National Cancer Institute by Dr. Stuart Winter. Coding information was
provided by Dr. James Anderson. Samples were obtained from 18 children and young
adults who were diagnosed with rhabdomyosarcoma and consented to have their tumor
samples stored in the Children’s Oncology Group (COG) Cell Bank (Columbus, OH). The
patients then received treatment on COG studies D9502 (n = 1), D9602 (n = 7), D9802 (n
= 1), or D9803 (n = 9), depending on the treatment era at the time of diagnosis.
Molecular and protein findings were compared with the original histological diagnoses,
annotated patient demographic features, staging, grouping and event free survival
associated with the treatment studies.

3.3.4 Immunofluorescence
Cells were grown on #1.5 22mm coverslips until nearly confluent. Cells were then fixed
in 4% formaldehyde in PBS for 20min and washed 3X in PBS. Cells were permeabilized in
0.4% Triton X-100 in PBS with 1% NGS at 4°C for 5min and then washed 3X in PBS with
1% NGS. Cells were incubated for 1hr with primary antibody in PBS with 1% NGS and
then washed 3X in PBS with 1% NGS. Cells were incubated in the appropriate
fluorophore-conjugated secondary antibody for 1hr in PBS with 1% NGS. Cells were
washed 4X in HEPES buffered saline and then mounted with Vectashield containing DAPI
(cat. # H-1200, Vector Laboratories, Burlingame, CA) and sealed with nail polish. Cell
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images were acquired with a CoolSNAP HQ (Photometrics, Tuscon, AZ) on a Zeiss
Axioplan2 (Thornwood, NY) using a Xenon light source and 63X (Plan-Apo, 1.4NA) lens
with Slidebook software Version 4.2 (Intelligent Imaging Innovations, Denver, CO).
Paraffin-embedded rhabdomyosarcoma tissue samples were obtained and mounted on
slides. The samples were deparaffinized and rehydrated by taking the slides through two
changes of each of the following baths: Citrisolve, 100% ethanol, 95% ethanol, 80%
ethanol, 70% ethanol, dH2O, and PBS. Antigen retrieval was performed by placing the
slides into pre-warmed 10mM sodium citrate buffer and keeping them at 97°C for
10min. The slides were allowed to cool at room temperature for 30min and then were
washed 3X for 5min each in dH2O and 3X for 5min each in PBS. Samples were then
blocked in PBS with 0.3% Triton X-100 and 5% NGS for 1hr. Blocking buffer was replaced
with primary antibody diluted in PBS with 0.3% Triton X-100. The samples were
incubated in primary antibody overnight at 4°C. Samples were then washed 3X in PBS
with 0.1% Tween-20 and incubated in secondary antibody diluted in PBS with 0.3%
Triton X-100. Samples were washed 3X in PBS with 0.1% Tween-20 and counterstained
with DAPI for 5min. The slides were washed 4X in HEPES buffered saline, mounted with
Mowiol, and sealed with nail polish.
3.3.5 Fluorescence Resonance Energy Transfer
Cells were grown on #1.5 22mm coverslips until nearly confluent. Cells were then fixed
in 4% formaldehyde in PBS for 20min and then washed 3X in PBS. Cells were
permeabilized in 0.4% Triton X-100 in PBS with 1% NGS at 4°C for 5min and then washed
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3X in PBS with 1% NGS. Cells were incubated for 1hr in anti-SnoN antibody in PBS with
1% NGS and then washed 3X in PBS with 1% NGS. Cells were incubated in the Cy3conjugated secondary antibody for 1hr in PBS with 1% NGS. Cells were washed 3X in PBS
with 1% NGS and then incubated in Cy5 conjugated anti-Ski antibody for 1hr. Cells were
washed 3X in PBS and counter-stained with DAPI for 5min. Cells were washed 4X in
HEPES buffered saline and then mounted with Mowiol and sealed with nailpolish. Cell
images were acquired with a CoolSNAP HQ camera (Photometrics, Tuscon, AZ) on a
Zeiss Axioplan2 (Thornwood, NY) with a Xenon light source and 63X (Plan-Apo, 1.4NA)
lens with Slidebook software Version 4.2 (Intelligent Imaging Innovations, Denver, CO).
Images of the donor (Cy3) and the acceptor (Cy5) were obtained and then the acceptor
was photobleached for 2min. Post-photobleaching images were then obtained of each
channel. FRET calculations were performed using the Image J FRETcalc plugin using the
acceptor photobleaching method (Stepensky, 2007).
3.3.6 Statistics
Student’s t test and Spearman’s coefficient were performed in Microsoft Excel 2007
(Redmond, WA) using a spreadsheet from the Handbook of Biological Statistics with
assistance from Dr. Betty Skipper at the University of New Mexico (McDonald, 2007).

3.4 Results:
I performed immunofluorescence microscopy studies to determine the
subcellular distribution of Ski in different cell lines. Representative images can be seen
in Figures 12-14. We found that Ski was located primarily in the nucleus in A204
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(undifferentiated sarcoma) and LNCaP (prostate cancer) cell lines. In propagating HSMM
(human myoblast), HeLa (cervical cancer), RMZ-RC2 (alveolar RMS), Hs729T (RMS), and
RD (embryonal RMS) cells there was more Ski signal in the nucleus than in the
cytoplasm, but there was still considerable staining in the cytoplasm. SJRH30 (alveolar
RMS) and A673 (Ewing’s sarcoma) cells had as much Ski labeling in the cytoplasm as in
the nucleus and it was no longer easy to define the nucleus based solely on the Ski
staining. We looked at the staining intensity of Ski at several time points during
myogenic differentiation of the HSMM cell line. We allowed the cells to grow to
confluence and then changed them to a growth media consisting of 2% horse serum in
DMEM. We detected a slight gradual increase in cytoplasmic Ski staining as the
differentiation progressed. Cells at the 20 day time point had several areas of intense
cytoplasmic staining. However, in these cells it is still possible to delineate the nucleus
as it had more staining than the surrounding cytoplasm. There were also differences in
protein levels and localization between the RMS tumor samples. The images were
graded from 0 to 6 based on level of staining intensity ranging from no staining to very
high intensity, respectively. A Spearman’s rank correlation was performed as we were
dealing with non-parametric categories. We found that there is a statistically significant
negative correlation (p=0.0138) between Ski protein staining intensity and RMS tumor
group, while SnoN protein staining intensity had a non-significant positive correlation
(p=0.0926) with RMS tumor group (see Figures 15 and 16).
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Figure 12: Indirect immunofluorescence images of Ski labeled with either FITC or Cy3 secondary
antibodies are on the left and corresponding images with DAPI overlay are on the right. A & B are propagating
HSMM primary human skeletal muscle cells. C & D are HSMM cells after 20 days of differentiation. E & F are
SJRH30 RMS cells.
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Figure 13: Indirect immunofluorescence images of Ski labeled with either FITC or Cy3 secondary
antibodies are on the left and corresponding images with DAPI overlay are on the right. A & B are RD RMS cells. C &
D are HS729t RMS cells. E & F are RMZ-RC2 RMS cells.
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Figure 14: Indirect immunofluorescence images of Ski labeled with FITC secondary antibodies are on the
left and corresponding images with DAPI overlay are on the right. A & B are A673 Ewing’s sarcoma cells. C & D are
LNCaP prostate cancer cells. E & F are A204 sarcoma cells.
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Figure 15: Graphical representation of Ski protein intensity vs RMS tumor group illustrating a statistically
significant negative correlation (p=0.0138).
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Figure 16: Graphical representation of SnoN protein intensity vs tumor group illustrating a positive, but
not statistically significant, correlation (p=0.0926).
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Next we performed fluorescence resonance energy transfer (FRET) to determine
if Ski and SnoN were in close proximity to one another. We found differences between
cell lines as well as differences between the nucleus and the cytoplasm. In SJRH30 cells
we found that there was an average FRET value of 21 in the cytoplasm and 11 in the
nucleus. A Student’s T-test was performed to determine if the difference was significant
and we obtained a p-value of 0.003 (see Figure 17). However we found that in HeLa cells
the FRET value was less, although there was still a significant difference between
cytoplasmic and nuclear FRET with a p-value of 9.23*10-6 (see Figure 17). These results
indicate that there is more Ski/SnoN colocalization in the cytoplasm than in the nucleus.
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10
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Figure 17: FRET percentage in the nucleus and cytoplasm in SJRH30 RMS cells and HeLa cervical cancer
cells illustrating an increased level of FRET in the cytoplasm of both cell lines.

3.5 Discussion
We found that the subcellular localization of Ski varied in the different cell lines
that we examined. Ski localization in the RMS cell lines was in all cases at least partially
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cytoplasmic. The SJRH30 cell line in particular had strong cytoplasmic staining. This is an
alveolar RMS cell that has the t(2;13) translocation and an amplicon that includes CDK4
and GLI with an overexpression of CDK4 mRNA and protein (Khatib et al., 1993). Alveolar
RMS tumors as a group have a worse prognosis than other types of RMS tumors (Loeb
et al., 2008). The other three RMS cell lines that we examined also have Ski staining in
the cytoplasm but there was still noticeably more Ski in the nucleus. Of these cell lines,
one was an embryonal (RD), one was not classified (Hs729t), and the other cell line was
alveolar (RMZ-RC2) although it contains the t(1;13) translocation instead of the t(2;13)
translocation (Nanni et al., 1986). The A673 Ewing’s sarcoma cell line is the other cell
line that we found to have intense cytoplasmic Ski staining. Interestingly, this cell line
was established from a patient with a primary RMS although cytogenetics has shown
that it has the EWS/FLI1 fusion gene and therefore is a Ewing’s tumor cell line (MartinezRamirez et al., 2003).
The intensity of Ski staining in the RMS tumor tissue has a statistically significant
negative correlation with tumor group. The intensity of SnoN staining in these samples
trended to a positive correlation with tumor group but failed to be statistically
significant. Tumor group refers to the postsurgical status of the cancer. Group I is
localized tumor tissue that is removed with clean margins. Group II is localized tumor
tissue that has microscopic amounts of tumor left, or cancer that has spread to local
lymph nodes and may or may not have microscopic cancer remaining after surgery.
Group III has macroscopic tumor tissue remaining after surgery for local cancer. Group
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IV has metastatic tumor tissue at the time of diagnosis. This result suggests that lower
quantities of the Ski protein are found in higher tumor group RMS cancers, which are
more likely to have metastasized. And conversely, high Ski protein levels are correlated
with tumors that are less likely to act in an aggressive manner. This would imply that
either Ski is involved in the early stages of tumorigenesis or that the loss of Ski
expression is a precursor to tumorigenesis.
The HSMM myoblast cell line will differentiate into myotubes if allowed to grow
to confluence and placed in a low serum media (Linardic et al., 2005). This cell line has
also been converted to embryonal RMS-like cells when infected with retroviruses
encoding T/t-Ags, hTERT, and H-RasV12G (Linardic et al., 2005). We found mostly nuclear
Ski staining with a small amount in the cytoplasm while propagating. After 20 days of
low serum differentiation, Ski is found in both the nucleus and the cytoplasm, although
the overall intensity of staining appears to be less than in the propagating myoblasts. Ski
has been shown to be involved in regulating the transcription of muscle specific
transcription factors, regulating myogenesis (Colmenares et al., 1991; Ichikawa et al.,
1997). Ski is expressed in myoblasts and regulates terminal differentiation by activating
the transcription of MyoG through interactions with Six1 and Eya3 (Zhang and
Stavnezer, 2008). With the shift of Ski protein to the cytoplasm in late myogenesis it is
possible that Ski has a function during myogenesis other than acting as a transcription
factor.
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My FRET results indicate that Ski and SnoN are often within 10nm of each other
in both the nucleus and the cytoplasm. This result corroborates earlier studies that
found that when overexpressed, Ski and SnoN can be cross-linked and pulled down
together (Heyman and Stavnezer, 1994; Nagase et al., 1993; Zheng et al., 1997a).
However, my results show that in cells with only endogenous proteins, Ski and SnoN are
in close enough proximity to have functional interactions. The results also surprisingly
indicate that this interaction is occurring not only in the nucleus, but also in the
cytoplasm. This suggests that the cytoplasmic interaction of Ski and SnoN may have
important functional consequences. Ski and SnoN have each been shown to separately
interact with Smad proteins and pRb in the cytoplasm, but this is the first evidence of an
interaction between Ski and SnoN in the cytoplasm (Jacob et al., 2008; Krakowski et al.,
2005; Reed et al., 2001).
Ski and SnoN are unique proto-oncoproteins in that they can induce both
oncogenic transformation and terminal muscle differentiation when expressed at high
levels (Colmenares and Stavnezer, 1990; Fumagalli et al., 1993; Mimura et al., 1996).
The function of Ski in myogenesis is regulating the transcription of skeletal muscle
transcription factors (Zhang and Stavnezer, 2008). Ski and SnoN are also co-repressors
of TGFβ signaling and aberrant signaling within this pathway has been linked to
tumorigenesis in a number of solid tumors (Buijs et al., 2007). I originally hypothesize
that since RMS cells have characteristics of skeletal muscle, Ski may also be involved in
RMS tumorigenesis and/or progression (Loeb et al., 2008). Both of these cell types
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express Ski and the protein is localized to both the nucleus and the cytoplasm. There did
not appear to be a correlation between Ski localization and RMS subtype although this
may be because the genotype of tumors in each subtype is not identical. The difference
in Ski localization in myoblasts and RMS cells may indicate a different function for Ski in
each cell type. The co-localization of Ski and SnoN in the cytoplasm of the SJRH30 cells
may be necessary for this function. Determining the functional consequences of this
interaction will allow us to better understand the molecular basis of RMS and possibly
define new therapeutic targets. Additional studies will be required to determine if the
high amount of FRET in the SJRH30 cell line is RMS-specific or if it is specific to this
particular cell line. I have performed preliminary experiments with the MDA-MB-231
breast cancer cell line and the results are similar to those from the HeLa cell line.
Performing FRET analysis on differentiating myoblasts may help to determine if Ski and
SnoN may have a functional interaction during myogenesis.
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Chapter 4: Gene Expression
4.1 Abstract
Ski and SnoN are transcription factors, encoded by the SKI and SKIL genes,
respectively, that act as co-repressors of the Smad-mediated TGFβ signaling pathway.
The literature reports that Ski and SnoN are involved in several aspects of development
including neural tube formation, hematopoiesis, and myogenesis. Recent studies have
indicated that SKI is overexpressed in some cancers. We have examined the expression
of SKI and SKIL in several cancer cell lines, human myoblasts during differentiation, and
in rhabdomyosarcoma (RMS) tumor tissue. We confirm earlier findings that SKIL is
expressed at a higher level in ER-positive breast cell lines than in ER-negative cell lines.
We also found that there is a difference between the expression profiles in
differentiating primary human myoblasts and differentiating mouse myoblasts of the
C2C12 cell line. The gene expression profiles of the RMS tumor tissue showed trends
that may be significant with a larger sample size.

4.2 Introduction
Ski and SnoN are essential transcription factors that are involved in development
of muscle and neuronal cell lineages, double knockouts of either one have been found
to be lethal (Amaravadi et al., 1997; Berk et al., 1997; Kaufman et al., 2000; Shinagawa
et al., 2000). They are unique proto-oncoproteins in that they can induce both
oncogenic transformation and terminal muscle differentiation when expressed at high
levels (Ambrose et al., 1995; Barkas et al., 1986). Both proteins are prognostic in
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melanoma (Reed et al., 2001), esophageal squamous cell carcinoma (Akagi et al., 2008),
colorectal cancer (Buess et al., 2004) and breast cancer (Zhang et al., 2003). Several
potential mechanisms for Ski’s and SnoN’s involvement in cancer have been identified.
They are both co-repressors of Smad-mediated TGFβ signaling (Akiyoshi et al., 1999; Luo
et al., 1999; Stroschein et al., 1999; Vignais, 2000) in which Smad proteins are activated
by TGFβ receptors that have been bound by the appropriate ligand (Miyazono, 2000).
The Smads then shuttle to the nucleus where they form complexes on DNA, either
activating or repressing transcription, depending on what other proteins are within the
complex. Ski and SnoN have been shown to interact with histone deacetylases,
promoting changes in chromatin structure and subsequently inhibiting transcription
(Nomura et al., 1999). Both Ski and SnoN have been shown to sequester Smad proteins
in the cytoplasm (Kokura et al., 2003; Krakowski et al., 2005). This inhibits Smadmediated TGFβ signaling before the Smads can shuttle to the nucleus. Ski has also been
shown to activate the Wnt/β-catenin signaling pathway in melanoma (Chen et al., 2003).
Although Ski and SnoN have been found to be either overexpressed and/or located in
the cytoplasm in many types of cancer, little attention has been given to
rhabdomyosarcoma (RMS). This is predominately a cancer of childhood and the most
common soft-tissue sarcoma in children (Loeb et al., 2008). RMS has characteristics of
skeletal muscle, displaying muscle specific markers. As Ski and SnoN are involved in
myogenesis, we hypothesized that they may also be involved in RMS. To investigate this
issue, we examined the expression of SKI and SKIL mRNAs by performing quantitative
reverse transcriptase PCR (qRT-PCR) on several cancer cell lines and on RMS tumor
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tissue samples. We found that both genes are expressed at varying levels in both RMS
cell lines and tumor tissue. We also examined SKI and SKIL gene expression in
differentiating myoblasts to see if the gene expression was similar to that seen in the
RMS tumors.

4.3 Methods
4.3.1 Cell Lines and Cell Culture
HeLa, SJRH30, RD, HS729t, A204, and A673 cell lines were purchased from ATCC
(Manassas, VA). RMZ-RC2 cells were kindly provided by Drs. Lorena Landuzzi and PierLuigi Lollini at the Laboratory of Immunology and Biology of Metastasis, Cancer
Research Section, Department of Experimental Pathology in Bologna, Italy. MCF-7 and
MDA-MB-231 cells were kindly provided by Dr. Rebecca Hartley at the UNM HSC. LNCaP
cells were kindly provided by Dr. Marco Bisoffi at the UNM HSC. HSMM cells were
purchased from Cambrex (Walkersville, MD).
Hela, SJRH30, RMZ-RC2, RD, HS729t, A204, A673 LNCaP, and MCF-7 cells were cultured
in DMEM (cat. #12430-104, Gibco, Carlsbad, CA) with 10% FBS (cat. #16140-071 , Gibco)
100U/ml Penicillin and 100µg/ml Streptomycin (cat. #15140-122, Gibco). Clonetics
HSMM cells were grown in Sk-GM-2 media (cat. #CC-3245, Cambrex, Walkersville, MD).
HSMM cells were differentiated in DMEM with 2% horse serum (cat. #26050-070, Gibco)
and 100U/ml Penicillin and 100µg/ml Streptomycin. MDA-MB-231 cells were cultured in
DMEM/F12 (cat. #11320-082, Gibco) with 10% FBS and 100U/ml Penicillin and 100µg/ml
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Streptomycin. Low passage number cells of each cell line were seeded on #1.5 22mm
coverslips, allowed to attach and grow until nearly confluent.
4.3.2 Tumor Tissue
The RMS tumor samples were acquired from the Cooperative Human Tissue Network
(CHTN) at the National Cancer Institute by Dr. Stuart Winter. Coding information was
provided by Dr. James Anderson. Samples were obtained from 18 children and young
adults who were diagnosed with rhabdomyosarcoma and consented to have their tumor
samples stored in the Children’s Oncology Group (COG) Cell Bank (Columbus, OH). The
patients then received treatment on COG studies D9502 (n = 1), D9602 (n = 7), D9802 (n
= 1), or D9803 (n = 9), depending on the treatment regiment at the time of diagnosis.
Molecular and protein findings were compared with the original histological diagnoses,
annotated patient demographic features, staging, grouping and event free survival
associated with the treatment studies.
4.3.3 RNA Extraction
Cells were grown to near confluence in T-75cm2 flasks and then rinsed with PBS. RNA
was then collected using Trizol (cat. #15596-026, Invitrogen, Carlsbad, CA) according to
the manufacturer’s directions. RNA was snap frozen in liquid nitrogen and stored at 80°C until needed. Tumor tissue was handled at -80°C until placed in Trizol. Pieces of
~200mg tissue were cut off with a razor blade and placed in a prechilled microfuge tube.
The piece was immediately processed with a Tissue Terror until all visible pieces were
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gone (~1min). The samples were then processed according to the Trizol directions, snap
frozen, and stored at -80°C.
4.3.4 RT-PCR
RNA concentration was calculated using a spectrophotometer and 10µg was used in a
60µl reaction with the Turbo DNA-free kit (cat. #AM1907, Ambion, Austin, TX) to
normalize RNA levels. 4µl of that reaction was used in an RT-PCR reaction using the
AccuScript kit (cat. #6000184, Stratagene, La Jolla, CA) with the following modifications:
The reaction contained 1M Betaine (cat. #B0300, Sigma, St. Louis, MO) and 5% DMSO
(cat. #D9170, Sigma, St. Louis, MO) and the PCR program was 25°C for 5min, 40°C for
60min, 50°C for 10min, and then 95°C for 5min. Random primers supplied in the kit
were used for transcription.
4.3.5 Quantitative Reverse Transcriptase PCR
Quantitative reverse transcriptase PCR (qRT-PCR) was performed using TaqMan primers
and the TaqMan Gene Expression Master Mix. All reagents, biologicals, and disposables
were purchased from Applied Biosystems (Foster City, CA). The primers used were SKI
(Hs00161707_m1),

SKI

(Mm00448744_m1),

SKIL

(Hs00180524_m1),

SKIL

(Mm00456917_m1), and Eukaryotic 18S rRNA endogenous control (4333760F). All
reactions were done in triplicate and run in 96-well fast optical 0.1ml plates using the AB
7500 Fast System with the normal program.
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4.3.6 Statistics
Statistical analyses were performed using two-tailed Student’s t test and Spearman’s
coefficient for non-parametric testing using Microsoft Excel 2007 (Redmond, WA).

4.4 Results
We first examined the mRNA expression levels of SKI and SKIL in several different
human cancer cell lines using TaqMan primers for qRT-PCR and 18S rRNA as an
endogenous control (see Figure 18). All of the data in the gene expression studies were
normalized relative to HSMM day 0 expression levels. We found the highest expression
of SKI in the Ewing’s sarcoma cell line A673. The highest expression of SKIL was found in
the RMS cell line HS729t. The RMZ-RC2 alveolar RMS cell line had high SKIL expression,
although the SKI expression was roughly half of the other RMS cell lines. Our data from
the breast cancer cell lines showed that SKIL expression in the ER/PR positive cell lines
MCF-7 and T47D is higher than in the ER/PR negative cell lines MDA-MB-231 and nontumorigenic MCF-10A. Generally speaking, we found that most of the cancer cell lines
have higher SKIL expression than SKI expression.
Next, we examined mRNA expression during myogenic differentiation in both a
mouse myoblast cell line (C2C12) and a human skeletal muscle myoblast cell line
(HSMM). In the C2C12 cell line we saw a gradual increase in both SKI and SKIL mRNA
expression relative to time 0 that was sustained throughout the 15 days of
differentiation (see Figure 19). In contrast, the HSMM cell line demonstrated a decrease
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in SKI and SKIL expression (see Figure 20). SKIL expression levels returned to baseline by
day three while SKI remained lower than baseline throughout differentiation.
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Figure 18: Real-Time PCR data using TaqMan primers and 18S rRNA endogenous control. Levels were
normalized to HSMM 0hr samples. Most of the cancer cell lines tended to have higher relative SKIL expression than
SKI expression.
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Figure 19: Real-Time PCR data using TaqMan primers and 18S rRNA endogenous control. Levels were
normalized to HSMM 0hr samples. The expression of both SKI and SKIL are increasing throughout the
differentiation process.
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Figure 20: Real-Time PCR data using TaqMan primers and 18S rRNA endogenous control. Levels were
normalized to HSMM 0hr samples. The expression of Ski drops after the initial time point and then stays level. The
expression of SKIL is similar to the pattern seen in C2C12 cells.
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Figure 21: Real-Time PCR data using TaqMan primers and 18S rRNA endogenous control. Levels were
normalized to HSMM 0hr samples. There was no correlation between RMS subtype and the expression of SKI or
SKIL.
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Finally, we examined SKI and SKIL mRNA expression levels in RMS tumor samples
to see if they correlated with tumor histology, site or extent of primary disease, and size
of presenting tumor in a cohort of 18 patients with alveolar (n = 6), embryonal (n = 11)
or botryoidal rhabdomyosarcomas (n = 1). The mRNA expression of the samples did not
seem to correlate significantly with tumor subtype, age of the patient, or prognosis.
There was a considerable variation of expression levels across the samples, with a 16fold difference in SKI expression and an 18-fold difference in SKIL expression (see Figure
20). Again, we see that SKIL expression is higher than the expression of SKI in all of the
samples. Next we investigated whether Ski and SnoN ratios were linked to the tumor
histology. All Ski/SnoN ratios were less than 1.0. Using Student’s T-test, we found no
correlation between Ski and SnoN ratios with histologic features and, in addition, we
found no significant correlation with the other annotated patient demographic data.

4.5 Discussion
Ski and SnoN are co-repressors of TGFβ signaling and aberrant signaling within
this pathway has been linked to tumorigenesis in a number of solid tumors (Buijs et al.,
2007). Researchers have examined the gene expression of SKI and SKIL during
myogenesis in mouse cells and in several varieties of tumor cells (Colmenares and
Stavnezer, 1990; Fumagalli et al., 1993; Mimura et al., 1996). The only report of SKI or
SKIL gene expression in RMS is in a description on a novel splicing variant from the SKIL
gene that codes for the SnoI protein (Pearson-White, 1993). The expression of SKI and
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SKIL gene transcripts in several tissues including RMS tumor tissue, skeletal muscle,
myofiber, and myoblasts was examined. They found SKI and SKIL gene expression in all
of these samples, with the novel splicing variant in all but the skeletal muscle sample,
but at a lower expression level than the other transcripts. Since RMS is a cancer with
characteristics of skeletal muscle, and Ski and SnoN have been shown to be involved in
myogenesis, we examined several RMS cell lines and found that they expressed SKI and
SKIL transcripts. In order to further examine SKI and SKIL expression in RMS tissue, we
obtained tumor samples from the CHTN. We did not find that mRNA levels of Ski or
SnoN were associated with tumor histology, disease progression or site of location at
the time of diagnosis, leading us to conclude that Ski and SnoN mRNA levels may not be
clearly linked to tumorigenesis in rhabdomyosaroma.

However, because the TGFβ

pathway is vitally involved in muscle differentiation, and Ski and SnoN are commonly
shared in rhabdomyosarcoma, these oncogenes remain to be considered for targeted
therapy in this disease subtype. As observed, the Ski to SnoN ratio was always below
1.0. This may be skewed by our choice of normalizing cell line. It is also possible that the
HSMM cell line has a considerably higher SKI, or lower SKIL, gene expression than other
cells and tumor tissue. The Ct values from the Real-Time PCR data for SKI and SKIL are
within three cycles of each other in the HSMM 0hr time point, with SKI having a lower Ct
than SKIL. This particular cell line was chosen as the normalizer because we thought that
it would be more representative of a normal cell than cancer cell lines.
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The data from the cell lines illustrate that there is a wide range of SKI and SKIL
gene expression among different varieties of cancer. Previous research has looked at
SKIL expression in several breast cancer cell lines (Zhang et al., 2003). Our results
confirmed that SKIL expression is higher in ER/PR positive cell lines than in ER/PR
negative cell lines. The SKI expression was similar in all of the breast cancer cell lines.
The A673 Ewing’s sarcoma cell line is unique in that it has high expression of both SKI
and SKIL. There are no reports in the literature of Ski or SnoN being associated with
Ewing’s sarcoma although there is a potential explanation. Ewing’s sarcoma (including
the A673 cell line) has a characteristic t(11;22) translocation that produces a fusion
protein with a member of the ETS family (Hahm et al., 1999). This protein has been
shown to inhibit the TGFβ2 receptor making the cells unresponsive to TGFβ signaling
(Hahm et al., 1999). It is possible that the disruption of this pathway has an effect on the
expression of Ski and SnoN. The other interesting result in the cancer cell lines involves
the RMZ-RC2 alveolar RMS cell line. This cell line contain the t(1;13) translocation that
moves the SKI gene from chromosome 1 to chromosome 13 (Nanni et al., 1986). Since
the data shows that SKI expression in this cell line is roughly half that of the other RMS
cell lines, we speculate that the translocated gene may be silenced during
tumorigenesis.
SKI and SKIL expression has been examined before in the C2C12 mouse myoblast
cell line (Mimura et al., 1996). This is a cell line that will differentiate into myotubes
when grown to confluence and switched to a low serum media. The researchers used
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qRT-PCR to quantify the mRNA levels and found that SKIL expression showed a transient
increase at 12 hours while SKI expression stayed relatively even. They hypothesized that
the increase occurred at the entrance to G0 phase. We are not sure why we failed to
replicate this result as the reported increase was rather large (25-fold). The most
reasonable explanation is that different methods of quantification were employed. We
used a very accurate reverse transcriptase enzyme (AccuScipt) and added betaine and
DMSO to the reaction as there are some GC-rich regions in the transcript that are
difficult to transcribe. A stepped-temperature program was used to transcribe the cDNA
(see methods). We then used TaqMan gene specific probes to amplify the cDNA in a
qRT-PCR machine using 18S rRNA as the endogenous control. The other group used
standard protocol and MMLV enzyme, followed by competitive PC and GAPDH as the
endogenous control. In our initial experiments we examined 18S rRNA, GAPDH and
several other controls. We found that the 18S rRNA has less variation in its levels in
different cell lines relative to total RNA. Since the endogenous quantities of this RNA are
much higher than the other controls, small variations in quantities between samples
have less of an effect on the results. Therefore, we believe that our result is correct. As
more is learned about the role of Ski and SnoN in myogenesis, the function of these
proteins in RMS will become clearer. Our gene expression data show that they are
expressed at high levels in some RMS tumors and it seems unlikely that this is merely
coincidental.
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Chapter 5: Conclusions
5.1 Potential Impact
Rhabdomyosarcoma is the most common pediatric soft tissue sarcoma, with 350
cases diagnosed each year (Loeb et al., 2008). The two main variants of RMS are alveolar
and embryonal, with the latter accounting for about 60% of cases. The embryonal
variant resembles immature skeletal muscle, while alveolar RMS resembles lung
parenchyma. Both variants express muscle-specific antigens such as desmin and MyoD.
Five-year survival rates have been slowly increasing but are still in the mid-70s%.
Chromosome translocations are found in 77% of the alveolar variant cases and are of
either the t(2;13) or the t(1;13) type. The t(1;13) translocation is of interest with regard
to Ski because this translocation involves the PAX7 gene located on chromosome 1 from
p36.12-p36.2, just centromeric to the SKI gene at 1p36.3. In this situation the
translocated SKI gene is moved to chromosome 13. While we do not expect that the
gene would be damaged by translocation, it is possible that to be placed under the
influence of a different promoter. We examined the RMZ-RC2 RMS cell line that
reportedly contains this translocation (Nanni et al., 1986). We saw by qRT-PCR that the
SKI gene expression in this cell line is about half the level of the other RMS cell lines.
Based on these data, we believe that the translocated SKI gene is being at least partially
silenced in the new location. The Ski protein staining via immunofluorescence
microscopy was average in this cell line and there was moderate cytoplasmic
localization. Further examination into the correlation between mRNA and protein levels
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in this and the other RMS cell lines may provide us with more information into the
regulation of Ski.
A significant finding in our research is that Ski protein levels in RMS tumor tissue
are negatively correlated with tumor group. This suggests that higher Ski protein levels
are found in tumors that tend to be less aggressive. There is non-significant trend with
SnoN as a positive correlation. It is interesting that, in all of the RMS tumor samples and
most of the cancer cell lines that we examined, SnoN mRNA expression was higher than
Ski expression. However, when we examined the Ski to SnoN ratio in regard to the
tumor histology, we did not find any statistical trends. It is also interesting that Ski and
SnoN protein levels did not correspond well to gene expression. This would suggest that
post-transcriptional and post-translational regulation are more important than the
regulation of transcription.
Ski and SnoN are unusual in that they can both act as either oncoproteins or
tumor suppressors (Liu et al., 2001; Shinagawa et al., 2001). Part of the explanation for
this is that they have been found to interact with almost twenty different proteins
(Medrano, 2007); see Figure 1 in Chapter 1. The high number of interacting proteins also
means that the subcellular localization of Ski and SnoN needs to be carefully regulated
to prevent unwanted interaction. We have localized the NLS in Ski via site-directed
mutagenesis and the creation of Ski-GFP fusion constructs. The SV40 Large T Antigenlike NLS is necessary and sufficient for nuclear localization of Ski. This result agrees with
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work that was concurrently performed in another lab using a different mutation
strategy (Nagata et al., 2006).
The NLS results merge well with our data showing that Ski is phosphorylated
when in the cytoplasm. Our immunoprecipitation data show that Ski is phosphorylated
when located in the cytoplasm but not in the nucleus. In light of previous research
indicating that Ski is phosphorylated in a cell cycle dependant manner, we cannot ignore
that the cytoplasmic cell fractions also include whole cell fractions of cells undergoing
mitosis after the nuclear membrane has broken down (Marcelain and Hayman, 2005).
Because we are working with rapidly dividing cancer cells, it is possible that some of the
phosphorylated Ski is derived from the nuclei of cells in the process of cell division. It
may be interesting to synchronize the cells and see if Ski phosphorylation and
localization correlate or change during the cell cycle.
We believe that this research contributes interesting data to the existing
knowledge of Ski and SnoN. Completion of the studies on the mechanism of localization
will be a key step in moving Ski and SnoN research forward. The potential involvement
in of these proteins in RMS is intriguing and requires further attention. There is clearly
much more work to be done.

5.2 Future Studies
The next step in studying Ski localization is to determine if phosphorylation
regulates its localization. First, the residue(s) that are being phosphorylated need to be
determined. A quick search with an on-line search tool such as NetPhos
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(http://www.cbs.dtu.dk/services/NetPhos/), will identify likely residues that can then be
mutated using techniques that we used to construct the GFP vectors. Finding the
kinase(s) involved is a difficult process as kinases generally phosphorylate many proteins
and determining which one is responsible is very complex and out of the scope of this
lab.
In regard to the RMS tumor tissue work, future studies should be focused on
increasing the sample size. We originally obtained twenty samples, although coding data
for only 18 of these was available. With the samples we have we can perform protein
extractions and Western blots to verify the immunofluorescence data. We attempted
this once but did not obtain good quality protein samples from the extracts. A different
protein extraction protocol may yield better results. Another area of interest would be
to examine the DNA sequence of SKI and SKIL from the tumor samples. Although no
mutations in SKI or SKIL have been reported, it would be interesting to sequence the
samples to be certain. And finally, fluorescence in situ hybridization (FISH) would allow
us to examine the gene copy number to see if there are any amplifications or
translocations.

5.3 Critique
There is a potential issue with our NLS experiments. The endogenous Ski in
SJRH30 cells is found in both the nucleus and the cytoplasm. However, the Ski-GFP
fusion is almost exclusively localized to the nucleus when expressed in these same cells.
It is possible that the SKI gene is mutated in this cell line, although this cell line has been
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extensively used and there are no reports of any SKI gene mutations. Another possibility
is that the GFP fused to Ski is interfering with the normal function of Ski and its ability to
interact with the proteins necessary for nucleocytoplasmic transport.
While performing the initial immunofluorescence studies on the cancer cell lines,
we also did some immuno-electron microscopy (EM) studies to determine Ski and SnoN
subcellular localization. Our goal was to obtain high resolution images of Ski and SnoN
localization using these techniques. The problem that we encountered was that the
localization of Ski was much different using immuno-EM than when using
immunofluorescence microscopy (IFM). Since our data with the IFM matched the data
reported in the literature, we decided to abandon the EM work. The EM fixation method
and the commercial antibody that we were using may have been the issue. We did not
get a chance to repeat these experiments with the new polyclonal antibody to Ski that
we had made.
FRET microscopy has become a common method to determine protein colocalization. Recent literature report that it is possible to use either a CCD camera
obtaining images from a fluorescence microscope or confocal laser scanning microscope
(CLSM) to perform these experiments (Kenworthy, 2001). We performed some trials
with a Zeiss 510 META CLSM to determine if obtaining confocal slices would have any
effect on the results and we did not find any difference in the quality of data that we
obtained. However, obtaining FRET data on more cell lines may provide us with
important information regarding the Ski/SnoN interaction and its role in cancer. We
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attempted to use FRET with the CHTN samples, but the background fluorescence
prohibited us from obtaining useful data. More controls for the FRET studies should also
be performed including performing the technique with proteins that we know interact
and with proteins that we know do not interact.
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